Christopher J. Logothetis, M.D.

Peer-Reviewed Articles

1. Zhao Y, Ramesh N, Xu P, Sei E, Hu M, Bai S, Troncoso P, Aparicio AM, Logothetis CJ, Corn PG, Navin NE, Zurita AJ. Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer During Serial Therapy. Cancer Res, 2025. e-Pub 2025. PMID: 39992716.
2. Moussa MJ, Tabet GC, Siefker-Radtke AO, Xiao L, Wilson NR, Gao J, Logothetis CJ, Grivas P, Lee B, Shah AY, Msaouel P, Li R, Clemente LC, Zhao J, Tannir NM, Kamat AM, Hansel DE, Guo CC, Campbell MT, Alhalabi O. Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract. Cancer Med 14(2):e70594, 2025. e-Pub 2025. PMID: 39831734.
3. Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Mukhida SS, Gregg JR, Corn PG, Koutroumpakis E, McQuade JL, Frigo DE, Pilie PG, Huff C, Logothetis CJ, Hahn AW. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer 31(12), 2024. e-Pub 2024. PMID: 39324992.
4. Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, Chery L, Pisters LL, Ward JF, Gregg JR, Papadopoulos J, Kamat AM, Lozano M, Hoang A, Broom B, Wang X, Huff CD, Logothetis CJ, Troncoso P, Pilie PG, Davis JW. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int 134(3):449-458, 2024. e-Pub 2024. PMID: 38837608.
5. Fizazi K, Le Teuff G, Fléchon A, Pagliaro L, Mardiak J, Geoffrois L, Laguerre B, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Cancel M, Juzyna B, Reckova M, Naoun N, Logothetis C, Culine S. Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. J Clin Oncol:JCO2301960. e-Pub 2024. PMID: 39167741.
6. Yu G, Corn PG, Mak CSL, Liang X, Zhang M, Troncoso P, Song JH, Lin SC, Song X, Liu J, Zhang J, Logothetis CJ, Melancon MP, Panaretakis T, Wang G, Lin SH. Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization. Proc Natl Acad Sci U S A 121(33):e2402903121, 2024. e-Pub 2024. PMID: 39102549.
7. Koutroumpakis E, Patel R, Khadke S, Bedrosian A, Kumar A, Kong Y, Connell B, Upadhyay J, Dani SS, Hahn AW, Logothetis CJ, Al-Kindi S, Butler J, Nohria A, Ganatra S, Deswal A. Associations of SGLT-2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy. Res Sq, 2024. e-Pub 2024. PMID: 39108488.
8. Lin SC, Yu G, Corn PG, Damasco J, Lee YC, Song JH, Navone NM, Logothetis CJ, Melancon MP, Panaretakis T, Lin SH. Radium-223 Treatment Produces Prolonged Suppression of Resident Osteoblasts and Decreased Bone Mineral Density in Trabecular Bone in Osteoblast Reporter Mice. Cancers (Basel) 16(14), 2024. e-Pub 2024. PMID: 39061241.
9. Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis. e-Pub 2024. PMID: 39019979.
10. Lin, SC, Yu, G, Corn, P, Damasco, J, Lee, Y, Song, J, Navone, NM, Logothetis, CJ, Melancon, MP, Panaretakis, T, Lin, S. Radium-223 Treatment Produces Prolonged Suppression of Resident Osteoblasts and Decreased Bone Mineral Density in Trabecular Bone in Osteoblast Reporter Mice. Cancers 16(14), 2024. e-Pub 2024. PMID: 39061241.
11. Aparicio AM, Tidwell RSS, Yadav SS, Chen JS, Zhang M, Liu J, Guo S, Pilié PG, Yu Y, Song X, Vundavilli H, Jindal S, Zhu K, Viscuse PV, Lebenthal JM, Hahn AW, Soundararajan R, Corn PG, Zurita-Saavedra A, Subudhi SK, Zhang J, Wang W, Huff C, Troncoso P, Allison JP, Sharma P, Logothetis CJ. A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 30(13):2751-2763, 2024. e-Pub 2024. PMID: 38683200.
12. Beckham TH, Rooney MK, Cifter G, Bernard V, McAleer MF, De BS, Tom MC, Perni S, Wang C, Swanson T, Tatsui CE, Alvarez-Breckenridge C, North R, Rhines LD, Tang C, Logothetis C, Amini B, Li J, Yeboa DN, Ghia AJ. Stereotactic radiosurgery for prostate cancer spine metastases: local control and fracture risk using a simultaneous integrated boost approach. J Neurosurg Spine:1-9. e-Pub 2024. PMID: 38875722.
13. Anselmino N, Labanca E, Shepherd PDA, Dong J, Yang J, Song X, Nandakumar S, Kundra R, Lee C, Schultz N, Zhang J, Araujo JC, Aparicio AM, Subudhi SK, Corn PG, Pisters LL, Ward JF, Davis JW, Vazquez ES, Gueron G, Logothetis CJ, Futreal A, Troncoso P, Chen Y, Navone NM. Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series. Clin Cancer Res 30(10):2272-2285, 2024. e-Pub 2024. PMID: 38488813.
14. Abida W, Hahn AW, Shore N, Agarwal N, Sieber P, Smith MR, Dorff T, Monk P, Rettig M, Patel R, Page A, Duff M, Xu R, Wang J, Barkund S, Pankov A, Wang A, Junttila MR, Multani PS, Daemen A, Chow Maneval E, Logothetis CJ, Morris MJ. Phase 1 Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing on Enzalutamide. Clin Cancer Res 30(6):1111-1120, 2024. e-Pub 2024. PMID: 38226958.
15. Paindelli C, Parietti V, Barrios S, Shepherd P, Pan T, Wang WL, Satcher RL, Logothetis CJ, Navone N, Campbell MT, Mikos AG, Dondossola E. Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo. Acta Biomater. e-Pub 2024. PMID: 38387748.
16. Yarmolinsky, J, Robinson, JW, Mariosa, D, Karhunen, V, Huang, J, Dimou, N, Murphy, N, Burrows, K, Bouras, E, Smith Byrne, K, Lewis, S, Galesloot, TE, Kiemeney, L, Vermeulen, SH, Martin, P, Albanes, D, Hou, L, Newcomb, PA, White, E, Wolk, A, Wu, AH, Le Marchand, L, Phipps, AI, Buchanan, DD, Landi, MT, Stevens, VL, Wang, Y, Albanes, D, Caporaso, N, Brennan, P, Amos, CI, Shete, S, Hung, RJ, Bickeböller, H, Risch, A, Houlston, R, Lam, S, Tardón, A, Chen, C, Bojesen, SE, Johansson, M, Wichmann, He, Christiani, DC, Rennert, G, Arnold, SM, Field, JK, Le Marchand, L, Melander, O, Brenner, H, Logothetis, CJ. Association between circulating inflammatory markers and adult cancer risk. EBioMedicine 100, 2024. e-Pub 2024. PMID: 38301482.
17. Logothetis CJ, Hahn AW. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 85(1):3-7, 2024. e-Pub 2024. PMID: 37210287.
18. Viscuse PV, Slack-Tidwell RS, Zhang M, Rohra P, Zhu K, San Lucas FA, Konnick E, Pilie PG, Siddiqui B, Logothetis CJ, Corn P, Subudhi SK, Pritchard CC, Soundararajan R, Aparicio A. Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Cancers (Basel) 15(24), 2023. e-Pub 2023. PMID: 38136389.
19. Gentile E, Hahn AW, Song JH, Hoang A, Shepherd PDA, Ramachandran S, Navone NM, Efstathiou E, Titus M, Corn PG, Lin SH, Logothetis CJ, Panaretakis T. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun 3(12):2531-2543, 2023. e-Pub 2023. PMID: 37930121.
20. Yu G, Corn PG, Mak CSL, Liang X, Zhang M, Troncoso P, Song JH, Lin SC, Song X, Liu J, Zhang J, Logothetis CJ, Melancon MP, Panaretakis T, Wang G, Lin SH. Prostate cancer-induced endothelial-to-osteoblast transition generates an immunosuppressive bone tumor microenvironment. bioRxiv, 2023. e-Pub 2023. PMID: 38076845.
21. Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X, Project BJ, Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury PP, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch CT, Cho K, Mcmahon BH, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder A, Stroomberg HV, Batra J, Chambers S, Horvath L, Clements JA, Tilly W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein S, Cook MB, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, MÉ P, Stanford JL, Ostrander EA, Koutros S, Beane Freeman LE, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Butler EN, Mohler JL, Taylor JA, Kogevinas M, Dierssen-Sotos T, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Pilie P, Yu Y, Bohlender RJ, Gu J, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Brenner H, Chen X, Holleczek B, Schöttker B, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet 55(12):2065-2074, 2023. e-Pub 2023. PMID: 37945903.
22. Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
23. Sakellakis MJ, Hahn AW, Ramachandran S, Zhang M, Hoang A, Song JH, Liu J, Wang F, Basu HS, Sheperd P, Wang X, Frigo DE, Lin SH, Panaretakis T, Zhang J, Navone N, Troncoso P, Logothetis CJ, Titus MA. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer Prostatic Dis 26(4):751-758, 2023. e-Pub 2023. PMID: 36100698.
24. Hahn AW, Thoman W, Koutroumpakis E, Abdulla A, Subudhi SK, Aparicio A, Basen-Enngquist K, Logothetis CJ, Gilchrist SC. Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience. Cardiooncology 9(1):33, 2023. e-Pub 2023. PMID: 37705024.
25. Mourkioti I, Polyzou A, Veroutis D, Theocharous G, Lagopati N, Gentile E, Stravokefalou V, Thanos DF, Havaki S, Kletsas D, Panaretakis T, Logothetis CJ, Stellas D, Petty R, Blandino G, Papaspyropoulos A, Gorgoulis VG. A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer. J Exp Clin Cancer Res 42(1):187, 2023. e-Pub 2023. PMID: 37507762.
26. Darst BF, Shen J, Madduri RK, Rodriguez AA, Xiao Y, Sheng X, Saunders EJ, Dadaev T, Brook MN, Hoffmann TJ, Muir K, Wan P, Le Marchand L, Wilkens L, Wang Y, Schleutker J, MacInnis RJ, Cybulski C, Neal DE, Nordestgaard BG, Nielsen SF, Batra J, Clements JA, Cancer BioResource AP, Grönberg H, Pashayan N, Travis RC, Park JY, Albanes D, Weinstein S, Mucci LA, Hunter DJ, Penney KL, Tangen CM, Hamilton RJ, MÉ P, Stanford JL, Koutros S, Wolk A, Sørensen KD, Blot WJ, Yeboah ED, Mensah JE, Lu YJ, Schaid DJ, Thibodeau SN, West CM, Maier C, Kibel AS, Cancel-Tassin G, Menegaux F, John EM, Grindedal EM, Khaw KT, Ingles SA, Vega A, Rosenstein BS, Teixeira MR, Investigators NP, Kogevinas M, Cannon-Albright L, Huff C, Multigner L, Kaneva R, Leach RJ, Brenner H, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Neuhausen SL, Isaacs WB, Nemesure B, Hennis AJ, Carpten J, Pandha H, De Ruyck K, Xu J, Razack A, Teo SH, Investigators CP, Newcomb LF, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Usmani N, Claessens F, Gago-Dominguez M, Castelao JE, Townsend PA, Crawford DC, Petrovics G, Casey G, Roobol MJ, Hu JF, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB, Wiklund F, Witte JS, Eeles RA, Kote-Jarai Z, Watya S, Gaziano JM, Justice AC, Conti DV, Haiman CA. Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry. Am J Hum Genet 110(7):1200-1206, 2023. e-Pub 2023. PMID: 37311464.
27. Vardaki I, Özcan SS, Fonseca P, Lin SH, Logothetis CJ, Yachnin J, Ullen A, Panaretakis T. Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration-resistant prostate cancer. Prostate 83(10):950-961, 2023. e-Pub 2023. PMID: 37074030.
28. Gregg JR, Kim J, Logothetis C, Hanash S, Zhang X, Manyam G, Muir K, Group UC, Giles GG, Stanford JL, Berndt SI, Kogevinas M, Brenner H, Eeles RA, Consortium P, Wei P, Daniel CR. Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer. Eur Urol Oncol 6(3):282-288, 2023. e-Pub 2023. PMID: 35995710.
29. Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN, de Bono JS, Petrylak DP, Fizazi K, Higano CS, Morris MJ, Rathkopf DE, Saad F, Ryan CJ, Small EJ, Kelly WK. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 41(15):JCO2202661, 2023. e-Pub 2023. PMID: 37040594.
30. Darst BF, Shen J, Madduri RK, Rodriguez AA, Xiao Y, Sheng X, Saunders EJ, Dadaev T, Brook MN, Hoffmann TJ, Muir K, Wan P, Le Marchand L, Wilkens L, Wang Y, Schleutker J, MacInnis RJ, Cybulski C, Neal DE, Nordestgaard BG, Nielsen SF, Batra J, Clements JA, Cancer BioResource AP, Grönberg H, Pashayan N, Travis RC, Park JY, Albanes D, Weinstein S, Mucci LA, Hunter DJ, Penney KL, Tangen CM, Hamilton RJ, MÉ P, Stanford JL, Koutros S, Wolk A, Sørensen KD, Blot WJ, Yeboah ED, Mensah JE, Lu YJ, Schaid DJ, Thibodeau SN, West CM, Maier C, Kibel AS, Cancel-Tassin G, Menegaux F, John EM, Grindedal EM, Khaw KT, Ingles SA, Vega A, Rosenstein BS, Teixeira MR, Investigators NP, Kogevinas M, Cannon-Albright L, Huff C, Multigner L, Kaneva R, Leach RJ, Brenner H, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Neuhausen SL, Isaacs WB, Nemesure B, Hennis AJ, Carpten J, Pandha H, De Ruyck K, Xu J, Razack A, Teo SH, Investigators CP, Newcomb LF, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Usmani N, Claessens F, GagoDominguez M, Castelao JE, Townsend PA, Crawford DC, Petrovics G, Casey G, Roobol MJ, Hu JF, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB, Wiklund F, Witte JS, Eeles RA, Kote-Jarai Z, Watya S, Gaziano JM, Justice AC, Conti DV, Haiman CA. Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry. medRxiv, 2023. e-Pub 2023. PMID: 37292833.
31. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer 185:178-215, 2023. e-Pub 2023. PMID: 37003085.
32. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol 83(3):267-293, 2023. e-Pub 2023. PMID: 36494221.
33. Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SK. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer 11(3), 2023. e-Pub 2023. PMID: 36948506.
34. Lin SC, Yu G, Lee YC, Song JH, Song X, Zhang J, Panaretakis T, Logothetis CJ, Komatsu Y, Yu-Lee LY, Wang G, Lin SH. Endothelial-to-osteoblast transition in normal mouse bone development. iScience 26(2):105994, 2023. e-Pub 2023. PMID: 36798441.
35. Mossa F, Robesti D, Sumankalai R, Corey E, Titus M, Kang Y, Zhang J, Briganti A, Montorsi F, Vellano CP, Marszalek JR, Frigo DE, Logothetis CJ, Gujral TS, Dondossola E. Subtype and site specific-induced metabolic vulnerabilities in prostate cancer. Mol Cancer Res 21(1):51-61, 2023. e-Pub 2023. PMID: 36112348.
36. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 613(7945):E3, 2023. e-Pub 2023. PMID: 36627494.
37. Yu G, Corn PG, Shen P, Song JH, Lee YC, Lin SC, Pan J, Agarwal SK, Panaretakis T, Pacifici M, Logothetis CJ, Yu-Lee LY, Lin SH. Retinoic acid receptor activation reduces metastatic prostate cancer bone lesions by blocking the endothelial-to-osteoblast transition. Cancer Res 82(17):3158-3171, 2022. e-Pub 2022. PMID: 35802768.
38. Bondaruk J, Jaksik R, Wang Z, Cogdell D, Lee S, Chen Y, Dinh KN, Majewski T, Zhang L, Cao S, Tian F, Yao H, Kus P, Chen H, Weinstein JN, Navai N, Dinney C, Gao J, Theodorescu D, Logothetis C, Guo CC, Wang W, McConkey D, Wei P, Kimmel M, Czerniak B. The origin of bladder cancer from mucosal field effects. iScience 25(7):104551, 2022. e-Pub 2022. PMID: 35747385.
39. Bondaruk J, Jaksik R, Wang Z, Cogdell D, Lee S, Chen Y, Dinh KN, Majewski T, Zhang L, Cao S, Tian F, Yao H, Kus P, Chen H, Weinstein JN, Navai N, Dinney C, Gao J, Theodorescu D, Logothetis C, Guo CC, Wang W, McConkey D, Wei P, Kimmel M, Czerniak B. Erratum: The origin of bladder cancer from mucosal field effects. iScience 25(7):104715, 2022. e-Pub 2022. PMID: 35811851.
40. Paindelli C, Casarin S, Wang F, Diaz-Gomez L, Zhang J, Mikos AG, Logothetis CJ, Friedl P, Dondossola E. Enhancing Radium 223 treatment efficacy by anti-beta 1 integrin targeting. J Nucl Med 63(7):1039-1045, 2022. e-Pub 2022. PMID: 34711616.
41. Wilson BE, Armstrong AJ, de Bono J, Sternberg CN, Ryan CJ, Scher HI, Smith MR, Rathkopf D, Logothetis CJ, Chi KN, Jones RJ, Saad F, De Porre P, Tran N, Hu P, Gillessen S, Carles J, Fizazi K, Joshua AM. Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. Eur J Cancer 170:296-304, 2022. e-Pub 2022. PMID: 35568679.
42. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke ON, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. Eur Urol 82(1):e18-e19, 2022. e-Pub 2022. PMID: 35440417.
43. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol 82(1):115-141, 2022. e-Pub 2022. PMID: 35450732.
44. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol 82(1):6-11, 2022. e-Pub 2022. PMID: 35393158.
45. Soundararajan R, Viscuse P, Pilie P, Liu J, Logotheti S, Laberiano Fernández C, Lorenzini D, Hoang A, Lu W, Soto LMS, Wistuba II, Xu M, Song X, Shepherd PDA, Navone NM, Tidwell RSS, Lozano G, Logothetis C, Zhang J, Long JP, Estecio MR, Tzelepi V, Aparicio AM. Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components. Cancers (Basel) 14(13), 2022. e-Pub 2022. PMID: 35805010.
46. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 606(7915):797-803, 2022. e-Pub 2022. PMID: 35705814.
47. Han H, Wang Y, Curto J, Gurrapu S, Laudato S, Rumandla A, Chakraborty G, Wang X, Chen H, Jiang Y, Kumar D, Caggiano EG, Capogiri M, Zhang B, Ji Y, Maity SN, Hu M, Bai S, Aparicio AM, Efstathiou E, Logothetis CJ, Navin N, Navone NM, Chen Y, Giancotti FG. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Rep 39(1):110595, 2022. e-Pub 2022. PMID: 35385726.
48. Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
49. Evagelopoulos, V, Charisiou, ND, Logothetis, M, Evagelopoulos, G, Logothetis, CJ. Cloud-Based Decision Support System for Air Quality Management. Climate 10(3), 2022. e-Pub 2022.
50. Evagelopoulos, V, Charisiou, ND, Logothetis, M, Evagelopoulos, G, Logothetis, CJ. Cloud-Based Decision Support System for Air Quality Management. Climate 10(3), 2022. e-Pub 2022.
51. Huynh-Le MP, Karunamuni R, Fan CC, Asona L, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir KR, Lophatananon A, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Haiman CA, Travis RC, Blot WJ, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Menegaux F, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Lu YJ, Watya S, Vega A, Kogevinas M, Wiklund F, Penney KL, Huff CD, Teixeira MR, Multigner L, Leach RJ, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, De Ruyck K, Ost P, Razack A, Newcomb LF, Fowke JH, Gamulin M, Abraham A, Claessens F, Castelao JE, Townsend PA, Crawford DC, Petrovics G, van Schaik RHN, MÉ P, Hu JJ, Zheng W, collaborators U, APCB, Investigators NP, Steering Committee IS, Collaborators, Investigators CP, Steering Committee PS, Consortium P, Mills IG, Andreassen OA, Dale AM, Seibert TM. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer Prostatic Dis. e-Pub 2022. PMID: 35152271.
52. Lee YC, Lin SC, Yu G, Zhu M, Song JH, Rivera K, Pappin DJ, Logothetis CJ, Panaretakis T, Wang G, Yu-Lee LY, Lin SH. Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition. Oncogene 41(6):757-769, 2022. e-Pub 2022. PMID: 34845375.
53. Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv 3(1), 2022. e-Pub 2022. PMID: 34993496.
54. Huynh-Le, M, Fan, CC, Karunamuni, R, Thompson, WK, Martinez, ME, Eeles, RA, Kote-Jarai, Z, Muir, K, Schleutker, J, Pashayan, N, Batra, J, Gronberg, H, Neal, D, Donovan, JL, Hamdy, FC, Martin, RM, Nielsen, SF, Nordestgaard, BG, Wiklund, F, Tangen, CM, Giles, GG, Wolk, A, Albanes, D, Travis, RC, Blot, WJ, Zheng, W, Sanderson, M, Stanford, JL, Mucci, L, West, CM, Kibel, AS, Cussenot, O, Berndt, SI, Koutros, S, Sorensen, KD, Cybulski, C, Grindedal, EM, Menegaux, F, Khaw, KT, Park, JY, Ingles, SA, Maier, C, Hamilton, R, Thibodeau, SN, Rosenstein, BS, Lu, YJ, Watya, S, Huff, C, Brenner, H, Logothetis, CJ. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature communications 12(1), 2021. e-Pub 2021. PMID: 33623038.
55. Huynh-Le, M, Fan, CC, Karunamuni, R, Thompson, WK, Martinez, ME, Eeles, RA, Kote-Jarai, Z, Muir, K, Schleutker, J, Pashayan, N, Batra, J, Gronberg, H, Neal, D, Donovan, JL, Hamdy, FC, Martin, RM, Nielsen, SF, Nordestgaard, BG, Wiklund, F, Tangen, CM, Giles, GG, Wolk, A, Albanes, D, Travis, RC, Blot, WJ, Zheng, W, Sanderson, M, Stanford, JL, Mucci, L, West, CM, Kibel, AS, Cussenot, O, Berndt, SI, Koutros, S, Sorensen, KD, Cybulski, C, Grindedal, EM, Menegaux, F, Khaw, KT, Park, JY, Ingles, SA, Maier, C, Hamilton, R, Thibodeau, SN, Rosenstein, BS, Lu, YJ, Watya, S, Huff, C, Brenner, H, Logothetis, CJ. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature communications 12(1), 2021. e-Pub 2021. PMID: 33623038.
56. Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel) 13(23), 2021. e-Pub 2021. PMID: 34885132.
57. Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. e-Pub 2021. PMID: 34789422.
58. Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. Eur J Cancer 157:259-267, 2021. e-Pub 2021. PMID: 34536949.
59. Labanca E, Bizzotto J, Sanchis P, Anselmino N, Yang J, Shepherd PDA, Paez A, Antico-Arciuch V, Lage-Vickers S, Hoang AG, Tang X, Raso MG, Titus M, Efstathiou E, Cotignola J, Araujo J, Logothetis C, Vazquez E, Navone N, Gueron G. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene 40(44):6284-6298, 2021. e-Pub 2021. PMID: 34584218.
60. Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. J Urol 206(5):1147-1156, 2021. e-Pub 2021. PMID: 34503355.
61. Salzillo TC, Mawoneke V, Weygand J, Shetty A, Gumin J, Zacharias NM, Gammon ST, Piwnica-Worms D, Fuller GN, Logothetis CJ, Lang FF, Bhattacharya PK. Measuring the Metabolic Evolution of Glioblastoma throughout Tumor Development, Regression, and Recurrence with Hyperpolarized Magnetic Resonance. Cells 10(10), 2021. e-Pub 2021. PMID: 34685601.
62. Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer 9(10), 2021. e-Pub 2021. PMID: 34663638.
63. Zhu M, Peng R, Liang X, Lan Z, Tang M, Hou P, Song JH, Mak CSL, Park J, Zheng SE, Huang A, Ma X, Chen R, Chang Q, Logothetis CJ, Jain AK, Lin SH, Katayama H, Hanash S, Wang G. P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis. Oncogene 40(41):6049-6056, 2021. e-Pub 2021. PMID: 34471235.
64. Grypari IM, Logotheti S, Zolota V, Troncoso P, Efstathiou E, Bravou V, Melachrinou M, Logothetis C, Tzelepi V. The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression. Medicine (Baltimore) 100(36):e27094, 2021. e-Pub 2021. PMID: 34516499.
65. Pan T, Lin SC, Lee YC, Yu G, Song JH, Pan J, Titus M, Satcher RL, Panaretakis T, Logothetis C, Yu-Lee LY, Lin SH. Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone. Oncogene 40(27):4592-4603, 2021. e-Pub 2021. PMID: 34127814.
66. Bruinsma SM, Nieboer D, Roobol MJ, Bangma CH, Verbeek JFM, Gnanapragasam V, Van Hemelrijck M, Frydenberg M, Lee LS, Valdagni R, Logothetis C, Steyerberg EW. Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative. J Urol 206(1):62-68, 2021. e-Pub 2021. PMID: 33617330.
67. Vardaki I, Corn P, Gentile E, Song JH, Madan N, Hoang A, Parikh N, Guerra L, Lee YC, Lin SC, Yu G, Santos E, Melancon MP, Troncoso P, Navone N, Gallick GE, Efstathiou E, Subudhi SK, Lin SH, Logothetis CJ, Panaretakis T. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res 27(11):3253-3264, 2021. e-Pub 2021. PMID: 33753455.
68. Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, Muir K, Lophatananon A, collaborators U, Schleutker J, Pashayan N, Batra J, BioResource A, Grönberg H, Walsh EI, Turner EL, Lane A, Martin RM, Neal DE, Donovan JL, Hamdy FC, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Haiman CA, Travis RC, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Wiklund F, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Vega A, Steering Committee IS, Collaborators, Kogevinas M, Penney KL, Teixeira MR, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, Razack A, Newcomb LF, Investigators CP, Gamulin M, Usmani N, Claessens F, Gago-Dominguez M, Townsend PA, Roobol MJ, Zheng W, Steering Committee PS, Mills IG, Andreassen OA, Dale AM, Seibert TM, Consortium P. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer Prostatic Dis 24(2):532-541, 2021. e-Pub 2021. PMID: 33420416.
69. Yu G, Shen P, Lee YC, Pan J, Song JH, Pan T, Lin SC, Liang X, Wang G, Panaretakis T, Logothetis CJ, Gallick GE, Yu-Lee LY, Lin SH. Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4. iScience 24(4):102388, 2021. e-Pub 2021. PMID: 33981975.
70. Gerdtsson AS, Setayesh SM, Malihi PD, Ruiz C, Carlsson A, Nevarez R, Matsumoto N, Gerdtsson E, Zurita A, Logothetis C, Corn PG, Aparicio AM, Hicks J, Kuhn P. Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer. Cancers (Basel) 13(5), 2021. e-Pub 2021. PMID: 33801459.
71. Spetsieris, N, Boukovala, M, Weldon, J, Tsikkinis, A, Hoang, A, Aparicio, A, Tu, S, Araujo, JC, Zurita-Saavedra, A, Corn, P, Pagliaro, LC, Kim, J, Wang, J, Subudhi, SK, Tannir, NM, Logothetis, CJ, Troncoso, P, Wang, X, Wen, S, Efstathiou, E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 19(1):22-31.e5, 2021. e-Pub 2021. PMID: 32675015.
72. Tomer, A, Nieboer, D, Roobol, MJ, Bjartell, A, Steyerberg, EW, Rizopoulos, D, Trock, BJ, Ehdaie, B, Carroll, PR, Filson, CP, Kim, J, Logothetis, CJ, Morgan, TM, Klotz, L, Pickles, T, Hyndman, E, Moore, CM, Gnanapragasam, V, Van Hemelrijck, M, Dasgupta, P, Bangma, CH, Villers, A, Rannikko, A, Valdagni, R, Perry, A, Hugosson, J, Rubio, J, Hefermehl, L, Lee, LS, Frydenberg, M, Kakehi, Y, Sugimoto, M, Van Der Kwast, T, Obbink, H, van der Linden, W, Hulsen, T, de Jonge, C, Kattan, M, Xinge, J, Muir, K, Lophatananon, A, Fahey, M, Zhang, L, Beckmann, K, Denton, B, Hayen, A, Boutros, PC, Guo, W, Benfante, N, Cowan, JE. Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. BJU international 127(1):96-107, 2021. e-Pub 2021. PMID: 32531869.
73. Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder MA, Iversen P, Batra J, Chambers S, Moya L, Horvath L, Clements JA, Tilley W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordström T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein SJ, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, MÉ P, Stanford JL, Ostrander EA, Geybels MS, Koutros S, Freeman LEB, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Burnet N, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Fontham ETH, Mohler J, Taylor JA, Kogevinas M, Llorca J, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Weaver B, Brenner H, Cuk K, Holleczek B, Saum KU, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, Meer D. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. e-Pub 2021. PMID: 33473200.
74. Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder MA, Iversen P, Batra J, Chambers S, Moya L, Horvath L, Clements JA, Tilley W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordström T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein SJ, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, MÉ P, Stanford JL, Ostrander EA, Geybels MS, Koutros S, Freeman LEB, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Burnet N, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Fontham ETH, Mohler J, Taylor JA, Kogevinas M, Llorca J, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Weaver B, Brenner H, Cuk K, Holleczek B, Saum KU, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, Meer D. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet 53(1):65-75, 2021. e-Pub 2021. PMID: 33398198.
75. Gregg JR, Surasi DS, Childs A, Moll N, Ward JF, Kim J, Daniel CR, Logothetis C, Bathala T, Davis JW. The Association of Peri-Prostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active Surveillance. J Urol 205(1):101097JU0000000000001321, 2021. e-Pub 2021. PMID: 32718204.
76. Han Y, Zhang M, Xu J, Li J, Xu Y, Thompson TC, Logothetis CJ, Sun D, Gu J. Genome-wide DNA methylation profiling of leukocytes identifies CpG methylation signatures of aggressive prostate cancer. Am J Cancer Res 11(3):968-978, 2021. e-Pub 2021. PMID: 33791167.
77. Brandão A, Paulo P, Maia S, Pinheiro M, Peixoto A, Cardoso M, Silva MP, Santos C, Eeles RA, Kote-Jarai Z, Muir K, Collaborators U, Schleutker J, Wang Y, Pashayan N, Batra J, BioResource A, Grönberg H, Neal DE, Nordestgaard BG, Tangen CM, Southey MC, Wolk A, Albanes D, Haiman CA, Travis RC, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Vega A, Steering Committee TIS, Collaborators, Kogevinas M, Wiklund F, Penney KL, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, Ruyck K, Razack A, Newcomb LF, Investigators CP, Lessel D, Usmani N, Claessens F, Gago-Dominguez M, Townsend PA, Roobol MJ, Steering Committee TPS, Consortium TP, Teixeira MR. The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers (Basel) 12(11), 2020. e-Pub 2020. PMID: 33158149.
78. Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, Ravoori MK, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon SL, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis CJ, Troncoso P, Navone NM. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res 26(18):4933-4946, 2020. e-Pub 2020. PMID: 32576626.
79. Malihi PD, Graf RP, Rodriguez A, Ramesh N, Lee J, Sutton R, Jiles R, Ruiz Velasco C, Sei E, Kolatkar A, Logothetis C, Navin NE, Corn P, Aparicio AM, Dittamore R, Hicks J, Kuhn P, Zurita AJ. Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressive prostate cancer. Clin Cancer Res 26(15):4143-4153, 2020. e-Pub 2020. PMID: 32341031.
80. Deng Y, Xie K, Logothetis CJ, Thompson TC, Kim J, Huang M, Chang DW, Gu J, Wu X, Ye Y. Genetic Variants in Epithelial Mesenchymal Transition Genes as Predictors of Clinical Outcomes in Localized Prostate Cancer. Carcinogenesis 41(8):1057-1064, 2020. e-Pub 2020. PMID: 32215555.
81. Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, Bossi A, AJMV DE, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Danielli R, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, McHenry MB, Chen A, Logothetis C, CA-, Investigators. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. e-Pub 2020. PMID: 32811715.
82. Ramesh N, Sei E, Tsai PC, Bai S, Zhao Y, Troncoso P, Corn PG, Logothetis C, Zurita AJ, Navin NE. Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing. Genome Biol 21(1):162, 2020. e-Pub 2020. PMID: 32631448.
83. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK. Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. Ann Oncol 31(7):930-941, 2020. e-Pub 2020. PMID: 32289380.
84. Yang G, Bondaruk J, Cogdell D, Wang Z, Lee S, Lee JG, Zhang S, Choi W, Wang Y, Liang Y, Wang G, Wang Y, Yao H, Dadhania V, Gao J, Logothetis C, Siefker-Radtke A, Kamat A, Dinney C, Theodorescu D, Kimmel M, Wei P, Guo CC, Weinstein JN, McConkey DJ, Czerniak B. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. Science 23(6):101201. e-Pub 2020. PMID: 32521509.
85. Xu J, Chang WS, Tsai CW, Bau DT, Davis JW, Thompson TC, Logothetis CJ, Gu J. Mitochondrial DNA copy number in peripheral blood leukocytes is associated with biochemical recurrence in prostate cancer patients in African Americans. Carcinogenesis 41(3):267-273, 2020. e-Pub 2020. PMID: 31408512.
86. Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med 12(537), 2020. e-Pub 2020. PMID: 32238575.
87. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectr 4(2):pkaa003, 2020. e-Pub 2020. PMID: 32368717.
88. Gregg JR, Davis JW, Reichard C, Wang X, Achim M, Chapin BF, Pisters L, Pettaway C, Ward JF, Choi S, Nguyen QN, Kuban D, Babaian R, Troncoso P, Madsen LT, Logothetis C, Kim J. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology 138:91-97, 2020. e-Pub 2020. PMID: 31899230.
89. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol 77(4):508-547, 2020. e-Pub 2020. PMID: 32001144.
90. Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer 127:67-75, 2020. e-Pub 2020. PMID: 31986451.
91. Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clin Cancer Res 26(5):990-999, 2020. e-Pub 2020. PMID: 31941830.
92. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DA. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer 126(3):506-514, 2020. e-Pub 2020. PMID: 31742674.
93. Tzelepi V, Logotheti S, Efstathiou E, Troncoso P, Aparicio A, Sakellakis M, Hoang A, Perimenis P, Melachrinou M, Logothetis C, Zolota V. Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progression. Pathology 52(2):218-227, 2020. e-Pub 2020. PMID: 31864524.
94. Efstathiou E, Titus M, Wen S, Troncoso P, Hoang A, Corn P, Prokhorova I, Araujo J, Dmuchowski C, Melhem-Bertrandt A, Patil S, Logothetis CJ. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol Oncol 3(1):119-127, 2020. e-Pub 2020. PMID: 31412017.
95. Xu J, Chang WS, Tsai CW, Bau DT, Xu Y, Davis JW, Thompson TC, Logothetis CJ, Gu J. Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients. EBioMedicine 52:102616, 2020. e-Pub 2020. PMID: 31981976.
96. Koinis F, Corn P, Parikh N, Song J, Vardaki I, Mourkioti I, Lin SH, Logothetis C, Panaretakis T, Gallick G. Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer. Cancers (Basel) 12(1), 2020. e-Pub 2020. PMID: 31963871.
97. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 30(12):e3, 2019. e-Pub 2019. PMID: 32041688.
98. Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, Gormley M, Ricci D, Titus M, Hoang A, Zurita AJ, Tran N, Peng W, Kheoh T, Molina A, Troncoso P, Logothetis CJ. Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. Eur Urol 76(4):418-424, 2019. e-Pub 2019. PMID: 31176622.
99. Dondossola E, Casarin S, Paindelli C, De-Juan-Pardo EM, Hutmacher DW, Logothetis CJ, Friedl P. Radium 223-Mediated Zonal Cytotoxicity of Prostate Cancer in Bone. J Natl Cancer Inst 111(10):1042-1050, 2019. e-Pub 2019. PMID: 30657953.
100. Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 20(10):1432-1443, 2019. e-Pub 2019. PMID: 31515154.
101. Aparicio A, Thall P, Logothetis C. Radiotherapy for metastatic prostate cancer. Lancet 394(10201):829-830, 2019. e-Pub 2019. PMID: 31498098.
102. Sinha KM, Bagheri-Yarmand R, Lahiri S, Lu Y, Zhang M, Amra S, Rizvi Y, Wan X, Navone N, Ozpolat B, Logothetis C, Gagel RF, Huard J. Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer. Oncogene 38(25):5038-5049, 2019. e-Pub 2019. PMID: 30858546.
103. van der Kwast TH, Helleman J, Nieboer D, Bruinsma SM, Roobol MJ, Surveillance Consortium MFGAPPCA, Trock B, Ehdaie B, Carroll P, Filson C, Kim J, Logothetis C, Morgan T, Klotz L, Pickles T, Hyndman E, Moore CM, Gnanapragasam V, Van Hemelrijck M, Dasgupta P, Bangma C, Roobol M, Villers A, Rannikko A, Valdagni R, Perry A, Hugosson J, Rubio-Briones J, Bjartell A, Hefermehl L, Shiong LL, Frydenberg M, Kakehi Y, Chung BH, van der Kwast T, Obbink H, van der Linden W, Hulsen T, de Jonge C, Kattan M, Xinge J, Muir K, Lophatananon A, Fahey M, Steyerberg E, Nieboer D, Zhang L, Guo W, Benfante N, Cowan J, Patil D, Tolosa E, Kim TK, Mamedov A, LaPointe V, Crump T, Kimberly-Duffell J, Santaolalla A, Nieboer D, Olivier JT, Rancati T, Ahlgren H, Mascarós J, Löfgren A, Lehmann K, Lin CH, Hirama H, Lee KS, Jenster G, Auvinen A, Bjartell A, Haider M, van Bochove K, Carter B, Gledhill S, Buzza M, Bangma C, Roobol M, Bruinsma S, Helleman J. Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. Eur Urol Oncol 2(3):333-336, 2019. e-Pub 2019. PMID: 31200849.
104. Paindelli C, Navone N, Logothetis CJ, Friedl P, Dondossola E. Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro. Biomaterials 197:296-304, 2019. e-Pub 2019. PMID: 30682644.
105. Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee JG, Zhang S, Cogdell D, Yang G, Choi W, Dinney C, Grossman HB, Logothetis C, Scherer SE, Guo CC, Zhang L, Wei P, Weinstein JN, Issa JP, Baggerly K, McConkey DJ, Czerniak B. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep 26(8):2241-2256.e4, 2019. e-Pub 2019. PMID: 30784602.
106. Zacharias N, Lee J, Ramachandran S, Shanmugavelandy S, McHenry J, Dutta P, Millward S, Gammon S, Efstathiou E, Troncoso P, Frigo DE, Piwnica-Worms D, Logothetis CJ, Maity SN, Titus MA, Bhattacharya P. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol Imaging Biol 21(1):86-94, 2019. e-Pub 2019. PMID: 29748904.
107. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. J Clin Oncol 37(5):JCO1801279, 2019. e-Pub 2019. PMID: 30576268.
108. Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet 51(2):363, 2019. e-Pub 2019. PMID: 30622367.
109. Wang Q, Gregg JR, Gu J, Ye Y, Chang DW, Davis JW, Thompson TC, Kim J, Logothetis CJ, Wu X. Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. Oncoimmunology 8(1):e1483303, 2019. e-Pub 2019. PMID: 30546938.
110. Dondossola E, Alexander S, Holzapfel BM, Filippini S, Starbuck MW, Hoffman RM, Navone N, De-Juan-Pardo EM, Logothetis CJ, Hutmacher DW, Friedl P. Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone. Sci Transl Med 10(452), 2018. e-Pub 2018. PMID: 30068572.
111. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machie. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet 50(7):928-936, 2018. e-Pub 2018. PMID: 29892016.
112. Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolo. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun 9(1):2256, 2018. e-Pub 2018. PMID: 29892050.
113. Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol 73(5):715-723, 2018. e-Pub 2018. PMID: 29258679.
114. Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24(3):696-707, 2018. e-Pub 2018. PMID: 29138344.
115. Pezaro CJ, Omlin A, Mastris K, Advisory Panel AC, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. Ann Oncol 28(8):1692-1694, 2017. e-Pub 2017. PMID: 28838209.
116. Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. e-Pub 2017. PMID: 28730293.
117. Lin SC, Lee YC, Yu G, Cheng CJ, Zhou X, Chu K, Murshed M, Le NT, Baseler L, Abe JI, Fujiwara K, deCrombrugghe B, Logothetis CJ, Gallick GE, Yu-Lee LY, Maity SN, Lin SH. Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Dev Cell 41(5):467-480.e3, 2017. e-Pub 2017. PMID: 28586644.
118. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. e-Pub 2017. PMID: 28655541.
119. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5):551-555, 2017. e-Pub 2017. PMID: 28346412.
120. Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal 10(480), 2017. e-Pub 2017. PMID: 28536297.
121. Aparicio A, Logothetis CJ. Reply to J.B. Aragon-Ching and D. Dalela et al. J Clin Oncol 35(8):917-918, 2017. e-Pub 2017. PMID: 27937088.
122. Tu H, Gu J, Meng QH, Kim J, Strom S, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett 13(3):1949-1957, 2017. e-Pub 2017. PMID: 28454349.
123. Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, Piulats JM, Gonzalez Mella P, Ng SS, Jaeger D, Parnis FX, Franke FA, Puente J, Carvajal R, Sengeløv L, McHenry MB, Varma A, van den Eertwegh AJ, Gerritsen W. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol 35(1):40-47, 2017. e-Pub 2017. PMID: 28034081.
124. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget 7(52):86280-86289, 2016. e-Pub 2016. PMID: 27861143.
125. Ferrara F, Staquicini DI, Driessen WH, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W. Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proc Natl Acad Sci U S A. e-Pub 2016. PMID: 27791181.
126. Maity SN, Titus MA, Gyftaki R, Wu G, Lu JF, Ramachandran S, Li-Ning-Tapia EM, Logothetis CJ, Araujo JC, Efstathiou E. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Sci Rep 6:35354, 2016. e-Pub 2016. PMID: 27748439.
127. Shu X, Ye Y, Gu J, He Y, Davis JW, Thompson TC, Logothetis CJ, Kim J, Wu X. Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis 37(10):965-71, 2016. e-Pub 2016. PMID: 27515962.
128. Kuhn P, Carlsson A, Luttgen MS, Dizon KK, Troncoso P, Corn P, Kolatkar A, Hicks JB, Logothetis C, Zurita AJ. Paired high-content analysis of prostate cancer cells in bone marrow and blood characterizes increased androgen receptor expression in tumor cell clusters. Clin Cancer Res. e-Pub 2016. PMID: 27702818.
129. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113(42):11919-11924, 2016. e-Pub 2016. PMID: 27698113.
130. Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget 7(29):46321-46334, 2016. e-Pub 2016. PMID: 27331874.
131. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int 118(1):68-76, 2016. e-Pub 2016. PMID: 26059275.
132. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer 122(12):1836-43, 2016. e-Pub 2016. PMID: 27018785.
133. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol 34(14):1652-9, 2016. e-Pub 2016. PMID: 26951312.
134. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine 7:85-93, 2016. e-Pub 2016. PMID: 27322462.
135. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34(12):1402-18, 2016. e-Pub 2016. PMID: 26903579.
136. Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res 22(6):1520-30, 2016. e-Pub 2016. PMID: 26546618.
137. Parker PA, Davis JW, Latini DM, Baum G, Wang X, Ward JF, Kuban D, Frank SJ, Lee AK, Logothetis CJ, Kim J. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int 117(3):469-77, 2016. e-Pub 2016. PMID: 25714186.
138. Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res 22(1):107-21, 2016. e-Pub 2016. PMID: 26272062.
139. Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia 18(1):1-9, 2016. e-Pub 2016. PMID: 26806347.
140. Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, Zhang J, Li-Ning-Tapia EM, Kapoor A, Wu CJ, Patel NB, Guo Z, Ramamoorthy V, Tieu TN, Heffernan T, Zhao D, Shang X, Khadka S, Hou P, Hu B, Jin EJ, Yao W, Pan X, Ding Z, Shi Y, Li L, Chang Q, Troncoso P, Logothetis CJ, McArthur MJ, Chin L, Wang YA, DePinho RA. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov 6(1):80-95, 2016. e-Pub 2016. PMID: 26701088.
141. Dayyani F, Zurita AJ, Nogueras-González GM, Slack R, Millikan RE, Araujo JC, Gallick GE, Logothetis CJ, Corn PG. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer 16:721, 2016. e-Pub 2016. PMID: 27599544.
142. Zhang T, Tseng C, Zhang Y, Sirin O, Corn PG, Li-Ning-Tapia EM, Troncoso P, Davis J, Pettaway C, Ward J, Frazier ML, Logothetis C, Kolonin MG. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat Commun 7:11674, 2016. e-Pub 2016. PMID: 27241286.
143. Tu H, Gu J, Meng QH, Kim J, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget 6(39):41988-96, 2015. e-Pub 2015. PMID: 26515605.
144. Lee YC, Lin SC, Yu G, Cheng CJ, Liu B, Liu HC, Hawke DH, Parikh NU, Varkaris A, Corn P, Logothetis C, Satcher RL, Yu-Lee LY, Gallick GE, Lin SH. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res 75(22):4949-59, 2015. e-Pub 2015. PMID: 26530902.
145. Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol 68(4):570-7, 2015. e-Pub 2015. PMID: 25985882.
146. Zurita AJ, Pisters LL, Wang X, Troncoso P, Dieringer P, Ward JF, Davis JW, Pettaway CA, Logothetis CJ, Pagliaro LC. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis 18(3):276-80, 2015. e-Pub 2015. PMID: 26171883.
147. Pasqualini R, Millikan RE, Christianson DR, Cardó-Vila M, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W. Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study. Cancer 121(14):2411-21, 2015. e-Pub 2015. PMID: 25832466.
148. Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A 112(27):8403-8, 2015. e-Pub 2015. PMID: 26080435.
149. Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, Schrijvers D, van den Eertwegh AJ, Li W, Molina A, Griffin TW, Kheoh T, Ricci DS, Zelinsky K, Rathkopf DE, Scher HI, Ryan CJ. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clin Cancer Res 21(7):1621-7, 2015. e-Pub 2015. PMID: 25593303.
150. Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ. Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. J Clin Oncol 33(12):1356-63, 2015. e-Pub 2015. PMID: 25624432.
151. Lee YC, Gajdosik MS, Josic D, Clifton JG, Logothetis C, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Mol Cell Proteomics 14(3):471-83, 2015. e-Pub 2015. PMID: 25527621.
152. Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci U S A 112(12):3776-81, 2015. e-Pub 2015. PMID: 25762070.
153. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, Investigators C. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152-60, 2015. e-Pub 2015. PMID: 25601341.
154. Mintz PJ, Rietz AC, Cardó-Vila M, Ozawa MG, Dondossola E, Do KA, Kim J, Troncoso P, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer. Proc Natl Acad Sci U S A 112(8):2515-20, 2015. e-Pub 2015. PMID: 25675522.
155. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. Eur Urol 67(1):53-60, 2015. e-Pub 2015. PMID: 24882673.
156. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121(1):69-76, 2015. e-Pub 2015. PMID: 25155428.
157. Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol 15(13):1442-50, 2014. e-Pub 2014. PMID: 25456363.
158. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). Eur Urol 66(5):815-25, 2014. e-Pub 2014. PMID: 24647231.
159. Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. J Clin Oncol 32(33):3705-15, 2014. e-Pub 2014. PMID: 25311217.
160. Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI. Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. J Clin Oncol 32(30):3391-9, 2014. e-Pub 2014. PMID: 25225437.
161. He Y, Gu J, Strom S, Logothetis CJ, Kim J, Wu X. The Prostate Cancer Susceptibility Variant rs2735839 Near KLK3 Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients. Clin Cancer Res 20(19):5133-9, 2014. e-Pub 2014. PMID: 25274378.
162. Bilen MA, Reyes A, Bhowmick D, Maa A, Bast R, Pisters LL, Lin SH, Logothetis CJ, Tu SM. Variant prostate carcinoma and elevated serum CA-125. Can J Urol 21(5):7442-8, 2014. e-Pub 2014. PMID: 25347368.
163. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med 6(252):252ra122, 2014. e-Pub 2014. PMID: 25186177.
164. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw 12(7):993-8, 2014. e-Pub 2014. PMID: 24994920.
165. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20(11):2846-50, 2014. e-Pub 2014. PMID: 24727321.
166. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, Investigators C. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700-12, 2014. e-Pub 2014. PMID: 24831977.
167. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 74(6):1651-60, 2014. e-Pub 2014. PMID: 24473064.
168. Gorlov IP, Yang JY, Byun J, Logothetis C, Gorlova OY, Do KA, Amos C. How to get the most from microarray data: advice from reverse genomics. BMC Genomics 15(1):223, 2014. e-Pub 2014. PMID: 24656147.
169. Gorlova O, Fedorov A, Logothetis C, Amos C, Gorlov I. Genes with a large intronic burden show greater evolutionary conservation on the protein level. BMC Evol Biol 14(1):50, 2014. e-Pub 2014. PMID: 24629165.
170. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 14(13):1307-16, 2013. e-Pub 2013. PMID: 24211163.
171. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309-22, 2013. e-Pub 2013. PMID: 24315100.
172. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 14(12):1193-9, 2013. e-Pub 2013. PMID: 24075621.
173. Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI, Investigators C. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 49(17):3648-57, 2013. e-Pub 2013. PMID: 23973186.
174. Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE. Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer 133(7):1536-46, 2013. e-Pub 2013. PMID: 23526299.
175. Autio KA, Bennett AV, Jia X, Fruscione M, Beer TM, George DJ, Carducci MA, Logothetis CJ, Kane RC, Sit L, Rogak L, Morris MJ, Scher HI, Basch EM. Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. J Oncol Pract 9(5):223-9, 2013. e-Pub 2013. PMID: 23943897.
176. Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, Logothetis CJ, Hung MC, Zhang S, Lin HK. Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression. Cell 154(3):556-68, 2013. e-Pub 2013. PMID: 23911321.
177. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate Cancer. Cancer Discov 3(8):849-61, 2013. e-Pub 2013. PMID: 23811619.
178. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clin Cancer Res 19(13):3621-30, 2013. e-Pub 2013. PMID: 23649003.
179. Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate 73(9):979-85, 2013. e-Pub 2013. PMID: 23371521.
180. Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, McIntyre BW, Logothetis CJ, Gallick GE, Lin SH. Targeting Constitutively Activated β1 Integrin inhibits Prostate Cancer Metastasis. Mol Cancer Res 11(4):405-17, 2013. e-Pub 2013. PMID: 23339185.
181. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol 31(4):412-9, 2013. e-Pub 2013. PMID: 23169517.
182. Efstathiou E, Karlou M, Wen S, Hoang A, Pettaway CA, Pisters LL, Maity S, Troncoso P, Logothetis CJ. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate 73(2):153-61, 2013. e-Pub 2013. PMID: 22753310.
183. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. Int J Radiat Oncol Biol Phys 85(1):e39-46, 2013. e-Pub 2013. PMID: 23102837.
184. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, Investigators C. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138-48, 2013. e-Pub 2013. PMID: 23228172.
185. Zhao H, Logothetis CJ, Gorlov IP, Zeng J, Dai J. Modified logistic regression models using gene coexpression and clinical features to predict prostate cancer progression. Comput Math Methods Med 2013:917502, 2013. e-Pub 2013. PMID: 24367394.
186. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 13(12):1210-7, 2012. e-Pub 2012. PMID: 23142059.
187. Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate 72(15):1638-47, 2012. e-Pub 2012. PMID: 22457212.
188. Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer 107(9):1547-53, 2012. e-Pub 2012. PMID: 23033003.
189. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS, COU-AA- Investigators FT. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983-992, 2012. e-Pub 2012. PMID: 22995653.
190. Tu SM, Som A, Tu B, Logothetis CJ, Lee MH, Yeung SC. Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis. Br J Cancer 107(4):646-51, 2012. e-Pub 2012. PMID: 22805323.
191. Gorlov IP, Byun J, Logothetis CJ. In silico functional profiling of individual prostate cancer tumors: many genes, few functions. Cancer Genomics Proteomics 9(3):109-14, 2012. e-Pub 2012. PMID: 22593245.
192. Gorlov IP, Byun J, Zhao H, Logothetis CJ, Gorlova OY. Beyond comparing means: the usefulness of analyzing interindividual variation in gene expression for identifying genes associated with cancer development. J Bioinform Comput Biol 10(2):1241013, 2012. e-Pub 2012. PMID: 22809348.
193. Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Chow Maneval E, Logothetis CJ. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol 23(3):688-694, 2012. e-Pub 2012. PMID: 32018662.
194. Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Chow Maneval E, Logothetis CJ. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol 23(3):688-94, 2012. e-Pub 2012. PMID: 21821830.
195. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features. Clin Cancer Res 18(3):666-77, 2012. e-Pub 2012. PMID: 22156612.
196. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ. Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone. J Clin Oncol 30(6):637-43, 2012. e-Pub 2012. PMID: 22184395.
197. Ye X, Lee YC, Choueiri M, Chu K, Huang CF, Tsai WW, Kobayashi R, Logothetis CJ, Yu-Lee LY, Lin SH. Aberrant expression of katanin p60 in prostate cancer bone metastasis. Prostate 72(3):291-300, 2012. e-Pub 2012. PMID: 21681775.
198. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23(1):46-52, 2012. e-Pub 2012. PMID: 21464158.
199. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23(1):46-52, 2012. e-Pub 2012. PMID: 32018383.
200. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study. Cancer 118(1):63-71, 2012. e-Pub 2012. PMID: 21976132.
201. Gorlov IP, Logothetis CJ, Fang S, Gorlova OY, Amos C. Building a statistical model for predicting cancer genes. PLoS One 7(11):e49175, 2012. e-Pub 2012. PMID: 23166609.
202. Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE. Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways. PLoS One 7(12):e51189, 2012. e-Pub 2012. PMID: 23300537.
203. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs 20(12):1677-84, 2011. e-Pub 2011. PMID: 22035268.
204. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer. J Natl Cancer Inst 103(22):1665-1675, 2011. e-Pub 2011. PMID: 21917607.
205. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3(111):111ra121, 2011. e-Pub 2011. PMID: 22133722.
206. Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A 108(46):18637-18642, 2011. e-Pub 2011. PMID: 22049339.
207. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response. Clin Cancer Res 17(14):4854-61, 2011. e-Pub 2011. PMID: 21632851.
208. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, Biologically Meaningful Prostate Cancer After 1 Year of Androgen Ablation and Docetaxel Treatment. J Clin Oncol 29(18):2574-81, 2011. e-Pub 2011. PMID: 21606419.
209. Tzelepi V, Karlou M, Wen S, Hoang A, Logothetis C, Troncoso P, Efstathiou E. Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling. Histopathology 58(7):1037-47, 2011. e-Pub 2011. PMID: 21707705.
210. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 71(8):846-56, 2011. e-Pub 2011. PMID: 21456067.
211. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, Investigators C. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995-2005, 2011. e-Pub 2011. PMID: 21612468.
212. Fitzpatrick JM, Bellmunt J, Dreicer R, Fleshner NE, Logothetis CJ, Moul JW, Tombal B, Zlotta A. Maximizing outcomes in genitourinary cancers across the treatment continuum. BJU Int 107 Suppl 2:1-12, 2011. e-Pub 2011. PMID: 21382149.
213. Bracarda S, Logothetis C, Sternberg CN, Oudard S. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU Int 107 Suppl 2:13-20, 2011. e-Pub 2011. PMID: 21382150.
214. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One 6(12):e28840, 2011. e-Pub 2011. PMID: 22194926.
215. Prantl L, Muehlberg F, Navone NM, Song YH, Vykoukal J, Logothetis CJ, Alt EU. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate 70(15):1709-15, 2010. e-Pub 2010. PMID: 20564322.
216. Zhao H, Logothetis CJ, Gorlov IP. Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression. Prostate Cancer Prostatic Dis 13(3):252-9, 2010. e-Pub 2010. PMID: 20386565.
217. Huang CF, Lira C, Chu K, Bilen MA, Lee YC, Ye X, Kim SM, Ortiz A, Wu FL, Logothetis CJ, Yu-Lee LY, Lin SH. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res 70(11):4580-9, 2010. e-Pub 2010. PMID: 20484040.
218. Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P. Morphologic Characterization of Preoperatively Treated Prostate Cancer: Toward a Post-Therapy Histologic Classification. Eur Urol 57(6):1030-8, 2010. e-Pub 2010. PMID: 19853370.
219. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861-71, 2010. e-Pub 2010. PMID: 20460488.
220. Tu SM, Lin SH, Podoloff DA, Logothetis CJ. Multimodality Therapy: Bone-targeted Radioisotope Therapy of Prostate Cancer. Clin Adv Hematol Oncol 8(5):341-51, 2010. e-Pub 2010. PMID: 20551894.
221. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis 13(1):6-11, 2010. e-Pub 2010. PMID: 19581923.
222. Efstathiou E, Logothetis CJ. A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res 16(4):1100-7, 2010. e-Pub 2010. PMID: 20145177.
223. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing genes associated with prostate cancer development. BMC Cancer 10:599, 2010. e-Pub 2010. PMID: 21044312.
224. Byun J, Logothetis CJ, Gorlov IP. Housekeeping genes in prostate tumorigenesis. Int J Cancer 125(11):2603-8, 2009. e-Pub 2009. PMID: 19551858.
225. Araujo JC, Poblenz A, Corn P, Parikh NU, Starbuck MW, Thompson JT, Lee F, Logothetis CJ, Darnay BG. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation. Cancer Biol Ther 8(22):2151-7, 2009. e-Pub 2009. PMID: 19855158.
226. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics 2:48, 2009. e-Pub 2009. PMID: 19653896.
227. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 104(4):456-60, 2009. e-Pub 2009. PMID: 19338544.
228. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol 27(20):3319-3324, 2009. e-Pub 2009. PMID: 19414670.
229. Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, Old LJ, Logothetis CJ, Sharma P. NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells. Clin Cancer Res 15(6):2130-9, 2009. e-Pub 2009. PMID: 19276258.
230. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):306-20, 2009. e-Pub 2009. PMID: 19244175.
231. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106(8):2729-34, 2009. e-Pub 2009. PMID: 19202079.
232. Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn P. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther 8(3):245-52, 2009. e-Pub 2009. PMID: 19106640.
233. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer 7(1):51-7, 2009. e-Pub 2009. PMID: 19213669.
234. Gorlov IP, Gallick GE, Gorlova OY, Amos C, Logothetis CJ. GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One 4(8):e6511, 2009. e-Pub 2009. PMID: 19652704.
235. Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG. Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther 7(10):1619-27, 2008. e-Pub 2008. PMID: 19018165.
236. Mathew P, Thall PF, Wen S, Bucana C, Jones D, Horne E, Oh WK, Morris MJ, Lee YC, Logothetis CJ, Lin SH, Fidler IJ. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Br J Cancer 99(9):1426-32, 2008. e-Pub 2008. PMID: 18841158.
237. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105(39):14987-92, 2008. e-Pub 2008. PMID: 18818309.
238. Araujo J, Logothetis C. Targeting Src signaling in metastatic bone disease. Int J Cancer 124(1):1-6, 2008. e-Pub 2008. PMID: 18942061.
239. Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, Logothetis CJ, Lin SH. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res 6(8):1259-67, 2008. e-Pub 2008. PMID: 18708358.
240. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 118(8):2697-710, 2008. e-Pub 2008. PMID: 18618013.
241. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res 14(12):3729-36, 2008. e-Pub 2008. PMID: 18559590.
242. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27(39):5195-203, 2008. e-Pub 2008. PMID: 18490922.
243. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: Key to the effective treatment of prostate cancer. Clin Cancer Res 14(6):1599-602, 2008. e-Pub 2008. PMID: 18347159.
244. McDonnell TJ, Chari NS, Cho-Vega JH, Troncoso P, Wang X, Bueso-Ramos CE, Coombes K, Brisbay S, Lopez R, Prendergast G, Logothetis C, Do KA. Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics 1:1, 2008. e-Pub 2008. PMID: 18237448.
245. Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst 99(21):1613-22, 2007. e-Pub 2007. PMID: 17971530.
246. Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, Brown MA, Bouchillon K, Carter CM, Logothetis CJ, Kim J. Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate 67(15):1677-85, 2007. e-Pub 2007. PMID: 17879948.
247. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med 26(26):4687-702, 2007. e-Pub 2007. PMID: 17427204.
248. Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S, Collaborative Group MOEIPCT. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 8(11):994-1000, 2007. e-Pub 2007. PMID: 17942366.
249. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13(19):5816-24, 2007. e-Pub 2007. PMID: 17908974.
250. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27(5):596-603, 2007. e-Pub 2007. PMID: 17700537.
251. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH. A Secreted Isoform of ErbB3 Promotes Osteonectin Expression in Bone and Enhances the Invasiveness of Prostate Cancer Cells. Cancer Res 67(14):6544-8, 2007. e-Pub 2007. PMID: 17638862.
252. van Adelsberg J, Gann P, Ko AT, Damber JE, Logothetis C, Marberger M, Schmitz-Drager BJ, Tubaro A, Harms CJ, Roehrborn C. The VIOXX in prostate cancer prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin 23(9):2063-2070, 2007. e-Pub 2007. PMID: 17651539.
253. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer (Review). Cancer Immun 7:10 (Review), 2007. e-Pub 2007. PMID: 17591743.
254. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13(4):1224-31, 2007. e-Pub 2007. PMID: 17317833.
255. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107:2254-61, 2006. e-Pub 2006. PMID: 17029276.
256. Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene 25:6015-25, 2006. e-Pub 2006. PMID: 16682954.
257. Spurgers KB, Gold DL, Coombes KR, Bohnenstiehl NL, Mullins B, Meyn RE, Logothetis CJ, McDonnell TJ. Identification of Cell Cycle Regulatory Genes as Principal Targets of p53-mediated Transcriptional Repression. J Biol Chem 281(35):25134-42, 2006. e-Pub 2006. PMID: 16798743.
258. Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, Zhou X, Daliani DD. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 5(2):144-9, 2006. e-Pub 2006. PMID: 17026803.
259. Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 98(11):783-93, 2006. e-Pub 2006. PMID: 16757703.
260. Wang J, Do KA, Wen S, Tsavachidis S, McDonnell TJ, Logothetis CJ, Coombes KR. Merging microarray data, robust feature selection, and predicting prognosis in prostate cancer. Cancer Inform 2:87-97, 2006. e-Pub 2006. PMID: 19458761.
261. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 174(6):2186-90, 2005. e-Pub 2005. PMID: 16280761.
262. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 23(31):7904-10, 2005. e-Pub 2005. PMID: 16258090.
263. Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA, Babaian RJ, Troncoso P. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11(19 Pt 1):6889-94, 2005. e-Pub 2005. PMID: 16203779.
264. Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev 14(7):1697-702, 2005. e-Pub 2005. PMID: 16030104.
265. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res 65(14):6189-98, 2005. e-Pub 2005. PMID: 16024620.
266. Cho-Vega JH, Troncoso P, Do KA, Rago C, Wang X, Tsavachidis S, Medeiros LJ, Spurgers K, Logothetis C, McDonnell TJ. Combined laser capture microdissection and serial analysis of gene expression from human tissue samples. Mod Pathol 18(4):577-84, 2005. e-Pub 2005. PMID: 15529182.
267. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7(3):280-93, 2005. e-Pub 2005. PMID: 15799828.
268. Wyatt RB, Sanchez-Ortiz RF, Wood CG, Ramirez E, Logothetis C, Pettaway CA. Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. J Natl Med Assoc 96(12):1587-93, 2004. e-Pub 2004. PMID: 15622688.
269. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 13(11 Pt 1):1710-6, 2004. e-Pub 2004. PMID: 15533897.
270. Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, Droz JP, Logothetis CJ. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 22(19):3868-76, 2004. e-Pub 2004. PMID: 15302906.
271. Assikis VJ, Do KA, Wen S, Wang X, Cho-Vega JH, Brisbay S, Lopez R, Logothetis CJ, Troncoso P, Papandreou CN, McDonnell TJ. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res 10(20):6770-8, 2004. e-Pub 2004. PMID: 15501953.
272. Strom SS, Gu Y, Zhang H, Troncoso P, Babaian RJ, Pettaway CA, Shete S, Spitz MR, Logothetis CJ. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 60(4):343-51, 2004. e-Pub 2004. PMID: 15264247.
273. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 24(5A):2897-903, 2004. e-Pub 2004. PMID: 15517894.
274. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 22(16):3323-9, 2004. e-Pub 2004. PMID: 15310776.
275. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22(11):2108-21, 2004. e-Pub 2004. PMID: 15169797.
276. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279(18):19191-200, 2004. e-Pub 2004. PMID: 14985354.
277. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 10(8):2587-93, 2004. e-Pub 2004. PMID: 15102659.
278. Spurgers KB, Coombes KR, Meyn RE, Gold DL, Logothetis CJ, Johnson TJ, McDonnell TJ. A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells. Oncogene 23(9):1712-23, 2004. e-Pub 2004. PMID: 14647426.
279. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 22(3):537-56, 2004. e-Pub 2004. PMID: 14752077.
280. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 171(1):145-8, 2004. e-Pub 2004. PMID: 14665863.
281. Zurita AJ, Troncoso P, Cardo-Vila M, Logothetis CJ, Pasqualini R, Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 64(2):435-9, 2004. e-Pub 2004. PMID: 14744752.
282. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2(9):835-43, 2003. e-Pub 2003. PMID: 14555702.
283. Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol 21(5):342-8, 2003. e-Pub 2003. PMID: 14670540.
284. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9(7):2587-97, 2003. e-Pub 2003. PMID: 12855635.
285. Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 97(12):2988-94, 2003. e-Pub 2003. PMID: 12784333.
286. Bruckheimer EM, Spurgers K, Weigel NL, Logothetis C, McDonnell TJ. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol 169(4):1553-7, 2003. e-Pub 2003. PMID: 12629413.
287. Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade J, rd, Logothetis CJ. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol 21(5):878-83, 2003. e-Pub 2003. PMID: 12610188.
288. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95(6):458-70, 2003. e-Pub 2003. PMID: 12644539.
289. Logothetis C, Tu SM, Navone N. Targeting prostate cancer bone metastases. Cancer 97(3):785-8, 2003. e-Pub 2003. PMID: 12548576.
290. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer 97(3):561-7, 2003. e-Pub 2003. PMID: 12548597.
291. Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study. Urol Oncol 21(1):21-6, 2003. e-Pub 2003. PMID: 12684123.
292. Pentz RD, Flamm AL, Pasqualini R, Logothetis CJ, Arap W. Revisiting ethical guidelines for research with terminal wean and brain-dead participants. Hastings Cent Rep 33(1):20-6, 2003. e-Pub 2003. PMID: 12613384.
293. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 21(1):57-63, 2003. e-Pub 2003. PMID: 12496764.
294. Volpert O, Luo W, Liu TJ, Estrera VT, Logothetis C, Lin SH. Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. J Biol Chem 277(38):35696-702, 2002. e-Pub 2002. PMID: 12122002.
295. Pu YS, Do KA, Luo W, Logothetis CJ, Lin SH. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. Anticancer Drugs 13(7):743-9, 2002. e-Pub 2002. PMID: 12187331.
296. Logothetis CJ. Challenge of locally persistent prostate cancer: an unresolved clinical dilemma. J Clin Oncol 20(15):3187, 2002. e-Pub 2002. PMID: 12149287.
297. Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas Mdel C, Olive M, Hsieh JT, Logothetis CJ, Navone NM. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 23(8):1289-96, 2002. e-Pub 2002. PMID: 12151346.
298. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20(14):3072-80, 2002. e-Pub 2002. PMID: 12118020.
299. Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, Logothetis CJ. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 20(13):2965-70, 2002. e-Pub 2002. PMID: 12089226.
300. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer 86(10):1555-60, 2002. e-Pub 2002. PMID: 12085204.
301. Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 94(10):2610-7, 2002. e-Pub 2002. PMID: 12173328.
302. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordonez NG, Troncoso P, Navone NM. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 8(3):775-81, 2002. e-Pub 2002. PMID: 11895908.
303. Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Jr, Smith TL, Williams D, Logothetis CJ. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20(5):1361-7, 2002. e-Pub 2002. PMID: 11870180.
304. Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, Logothetis C. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett 176(1):57-63, 2002. e-Pub 2002. PMID: 11790454.
305. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R. Steps toward mapping the human vasculature by phage display. Nat Med 8(2):121-7, 2002. e-Pub 2002. PMID: 11821895.
306. Pu, Y-S, K-A D, Luo W, Logothetis CJ, S-H L. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. Anti-Cancer Drugs 13:1-8, 2002. e-Pub 2002.
307. Fizazi K, Do KA, Wang X, Finn L, Logothetis CJ, Amato RJ. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Ann Oncol 13(1):125-34, 2002. e-Pub 2002. PMID: 11863094.
308. Coombes KR, Zhang L, Bueso-Ramos C, Brisbay S, Logothetis C, Roth J, Keating MJ, McDonnell TJ. TAD: a web interface and database for tissue microarrays. Appl Bioinformatics 1(3):155-8, 2002. e-Pub 2002. PMID: 15130842.
309. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, Williams D, Logothetis C. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 19(20):4005-13, 2001. e-Pub 2001. PMID: 11600601.
310. Newman RA, Yang J, Raymond M, Finlay V, Cabral F, Vourloumis D, Stephens LC, Troncoso P, Wu X, Logothetis CJ, Nicolaou KC, Navone NM. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol 48(4):319-26, 2001. e-Pub 2001. PMID: 11710633.
311. Honda T, Gjertsen BT, Spurgers KB, Briones F, Lee SJ, Hobbs ML, Meyn RE, Roth JA, Logothetis C, McDonnell TJ. Restoration of bax in prostate cancer suppresses tumor growth and augments therapeutic cell death induction. Anticancer Res 21(5):3141-6, 2001. e-Pub 2001. PMID: 11848465.
312. Fizazi K, Amato RJ, Beuzeboc P, Petit N, Bouhour D, Thiss A, Rebischung C, Chevreau C, Logothetis CJ, Droz JP. Germ cell tumors in patients infected by the human immunodeficiency virus. Cancer 92(6):1460-7, 2001. e-Pub 2001. PMID: 11745223.
313. Millikan RE, Plunkett WK, Smith TL, Williams DL, Logothetis CJ. Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin. Cancer 92(1):194-9, 2001. e-Pub 2001. PMID: 11443627.
314. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61(14):5652-9, 2001. e-Pub 2001. PMID: 11454720.
315. Millikan R, Baez L, Banerjee T, Wade J, Edwards K, Winn R, Smith TL, Logothetis C. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol Oncol 6(3):111-115, 2001. e-Pub 2001. PMID: 11344001.
316. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357(9253):336-41, 2001. e-Pub 2001. PMID: 11210994.
317. Schumacher G, Bruckheimer EM, Beham AW, Honda T, Brisbay S, Roth JA, Logothetis C, McDonnell TJ. Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. Int J Cancer 91(2):159-66, 2001. e-Pub 2001. PMID: 11146439.
318. Millikan, RE, Baez L, Banerjee T, Wade J, Edwards K, Winn R, Smith TL, Logothetis C. Randomized phase 2 trial of ketoconazole and ketoconazole /doxorubicin in androgen independent prostate cancer. . Urologic Oncology 6(3):111-115, 2001. e-Pub 2001. PMID: 11344001.
319. Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 89(3):615-8, 2000. e-Pub 2000. PMID: 10931461.
320. Ozen M, Hopwood VL, Balbay MD, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S. Correlation of non-random chromosomal aberrations in lymphocytes of prostate cancer patients with specific clinical parameters. Int J Oncol 17(1):113-7, 2000. e-Pub 2000. PMID: 10853027.
321. Kim J, Palmer JL, Finn L, Hodges S, Bowes VV, Deftos L, Murphy G, Logothetis C. The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate. Urol Oncol 5(3):97-103, 2000. e-Pub 2000. PMID: 10765015.
322. Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res 6(3):1190-7, 2000. e-Pub 2000. PMID: 10741751.
323. Pettaway CA, Pisters LL, Troncoso P, Slaton J, Finn L, Kamoi K, Logothetis CJ. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 18(5):1050-7, 2000. e-Pub 2000. PMID: 10694556.
324. Amato RJ, Millikan R, Daliani D, Wood L, Logothetis C, Pollack A. Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. Clin Cancer Res 6(1):72-7, 2000. e-Pub 2000. PMID: 10656434.
325. Lecrone V, Li W, Devoll RE, Logothetis C, Farach-Carson MC. Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins. Cell Calcium 27(1):35-42, 2000. e-Pub 2000. PMID: 10726209.
326. McCutcheon IE, Eng DY, Logothetis CJ. Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment. Cancer 86(11):2301-11, 1999. e-Pub 1999. PMID: 10590371.
327. Pisters LL, Pettaway CA, Hossan E, Evans R, Steiner MS, Wood CG, Troncoso P, McDonnell TJ, Fenstenmacher MJ, Logothetis CJ. Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results. Prostate Cancer Prostatic Dis 2(S3):S27, 1999. e-Pub 1999. PMID: 12496806.
328. Park DS, Prow DM, Amato RJ, Logothetis CJ. Management consideration in nonpulmonary visceral metastatic seminoma of testis. J Korean Med Sci 14(4):431-7, 1999. e-Pub 1999. PMID: 10485624.
329. Logothetis CJ. Introduction: a therapeutically relevant framework for the classification of human prostate cancer. Semin Oncol 26(4):369-74, 1999. e-Pub 1999. PMID: 10482179.
330. Luo W, Tapolsky M, Earley K, Wood CG, Wilson DR, Logothetis CJ, Lin SH. Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Ther 6(4):313-21, 1999. e-Pub 1999. PMID: 10419049.
331. Park DS, Prow DM, Amato RJ, Ro JY, Logothetis CJ. Clinical characteristics of metachronous bilateral testicular tumors in the chemotherapeutic era. Yonsei Med J 40(2):137-43, 1999. e-Pub 1999. PMID: 10333717.
332. Amato RJ, Bui C, Logothetis CJ. Estramustine in combination with vinblastine and mitomycin-C for patients with progressive androgen independent adenocarcinoma of the prostate. Prostate Cancer Prostatic Dis 2(2):83-87, 1999. e-Pub 1999. PMID: 12496843.
333. Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, Figg WD. Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. Br J Cancer 79(9):1588-93, 1999. e-Pub 1999. PMID: 10188911.
334. Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY, Luthra R, Logothetis C, Von Eschenbach AC, Grossman HB, Benedict WF, Batsakis JG. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 18(5):1185-96, 1999. e-Pub 1999. PMID: 10022124.
335. Ozen M, Hopwood VL, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S. Aneuploidy index in blood: a potential marker for early onset, androgen response, and metastasis in human prostate cancer. Urology 53(2):381-5, 1999. e-Pub 1999. PMID: 9933059.
336. Lin SH, Pu YS, Luo W, Wang Y, Logothetis CJ. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model. Anticancer Res 19(1A):337-40, 1999. e-Pub 1999. PMID: 10226564.
337. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 161(1):304-8, 1999. e-Pub 1999. PMID: 10037428.
338. Herrmann JL, Briones F, Jr, Brisbay S, Logothetis CJ, McDonnell TJ. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 17(22):2889-99, 1998. e-Pub 1998. PMID: 9879995.
339. Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet 106(2):105-9, 1998. e-Pub 1998. PMID: 9797773.
340. Logothetis CJ. Emerging strategies in the treatment of testis cancer. Curr Opin Urol 8(5):411-2, 1998. e-Pub 1998. PMID: 17039021.
341. Millikan RE, Logothetis CJ. Prospects for optimized clinical management of bladder cancer by application of phenotypic markers. J Natl Cancer Inst 90(14):1028-9, 1998. e-Pub 1998. PMID: 9672249.
342. Tu SM, Pagliaro LC, Banks ME, Amato RJ, Millikan RE, Bugazia NA, Madden T, Newman RA, Logothetis CJ. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin Cancer Res 4(5):1193-201, 1998. e-Pub 1998. PMID: 9607577.
343. Moss, TJ, Logothetis CJ, Wood CG. Immunocytochemical (ICC) analysis: An attractive alternative to reverse transcriptase-polymerase chain reaction (RT-PCR) in molecular staging of prostate cancer (PCa). . J Urol 159(5):292, 1998. e-Pub 1998.
344. Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M, Logothetis CJ. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 80(11):2128-32, 1997. e-Pub 1997. PMID: 9392335.
345. Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A, Logothetis CJ. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3(12 Pt 1):2371-6, 1997. e-Pub 1997. PMID: 9815636.
346. Millikan R, Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology (Williston Park) 11(11A):180-93, 1997. e-Pub 1997. PMID: 9430189.
347. Hu SX, Ji W, Zhou Y, Logothetis C, Xu HJ. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Res 57(16):3339-43, 1997. e-Pub 1997. PMID: 9269991.
348. Chaturvedi V, Li L, Hodges S, Johnston D, Ro JY, Logothetis C, von Eschenbach AC, Batsakis JG, Czerniak B. Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene 14(17):2059-70, 1997. e-Pub 1997. PMID: 9160886.
349. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157(2):569-74, 1997. e-Pub 1997. PMID: 8996359.
350. Sim SJ, Glassman AB, Ro JY, Lee JJ, Logothetis CJ, Liu FJ. Serum calcitonin in small cell carcinoma of the prostate. Ann Clin Lab Sci 26(6):487-95, 1996. e-Pub 1996. PMID: 8908318.
351. Tu SM, Delpassand ES, Jones D, Amato RJ, Ellerhorst J, Logothetis CJ. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol 2(6):191-7, 1996. e-Pub 1996. PMID: 21224168.
352. Hutter RV, Montie JE, Busch C, Crignon DJ, Lieber M, Logothetis C, Ragde H, Reuter VE. Current prognostic factors and their relevance to staging. Cancer 78(2):369-71, 1996. e-Pub 1996. PMID: 8674020.
353. Logothetis C, Swanson D, Amato R, Banks M, Finn L, Ayala A, Ro J, Babaian R, Dinney C, Ellerhorst J, Hall C, von Eschenbach A. Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol 155(4):1241-5, 1996. e-Pub 1996. PMID: 8632540.
354. Herrada J, Dieringer P, Logothetis CJ. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J Urol 155(2):620-3, 1996. e-Pub 1996. PMID: 8558675.
355. Logothetis CJ. Chemotherapy for invasive and metastatic bladder cancer. . Advances in Oncology 12(1):19-22, 1996. e-Pub 1996.
356. Hoosein, N, Abdul M, Logothetis CJ. Significance of neuroendocrine differentiation in prostatic carcinoma. The Cancer Journal 9(6):291-295, 1996. e-Pub 1996.
357. Amato, RJ, Ellerhorst J, Finn L, Logothetis CJ. Absence of anti-tumor activity with Prednisone in patients with progressive androgen-independent prostate carcinoma. Urologic Oncology 2(2):70-3, 1996. e-Pub 1996. PMID: 21224139.
358. Amato RJ, Ellerhorst J, Banks M, Logothetis CJ. Carboplatin and ifosfamide and selective consolidation in advanced seminoma. Eur J Cancer 31A(13):2223-8, 1995. e-Pub 1995. PMID: 8652247.
359. Amato R, Meyers C, Ellerhorst J, Finn L, Kilbourn R, Sella A, Logothetis C. A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma. Ann Oncol 6(9):911-4, 1995. e-Pub 1995. PMID: 8624294.
360. Tu SM, Hossan E, Amato R, Kilbourn R, Logothetis CJ. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 154(5):1719-22, 1995. e-Pub 1995. PMID: 7563331.
361. Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu SM, Amato RJ. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 13(9):2272-7, 1995. e-Pub 1995. PMID: 7666085.
362. Amato RJ, Ellerhorst J, Bui C, Logothetis CJ. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol Oncol 1(4):168-72, 1995. e-Pub 1995. PMID: 21224113.
363. Hoosein NM, Martin KJ, Abdul M, Logothetis CJ, Kaddurah-Daouk R. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells. Anticancer Res 15(4):1339-42, 1995. e-Pub 1995. PMID: 7654018.
364. Tu SM, Robinson ED, Amato RJ, Ellerhorst JA, Kilbourn RG, Logothetis CJ. A phase I study of FAP (5-Fluorouracil, α-interferon and cisplatin) combined with methotrexate for the treatment of advanced urothelial malignancies. Urol Oncol 1(4):156-60, 1995. e-Pub 1995. PMID: 21224110.
365. Abdul M, Logothetis CJ, Hoosein NM. Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 154(1):247-50, 1995. e-Pub 1995. PMID: 7776439.
366. Daliani DD, Eisenberg PD, Weems J, Lord R, Fueger R, Logothetis CJ. The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. J Urol 153(5):1587-91, 1995. e-Pub 1995. PMID: 7536271.
367. Nazario, A, Amato RJ, Hutchinson L, Bui C, Ellerhorst J, Logothetis CJ. Paclitaxel in extensively pretreated nonseminomatous germ cell tumors. Urologic Oncology 1(5):184-7, 1995. e-Pub 1995. PMID: 21224115.
368. Hoosein, N, Abdul M, McCabe R, Gero E, Deftos L, Banks M, Hodges S, Finn L, Logothetis CJ. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urologic Oncology 1(6):246-51, 1995. e-Pub 1995. PMID: 21224126.
369. Hsieh, JT, Wu HC, Wang Y, Song WT, Li W, Finn L, Logothetis CJ. Evidence for the existence of an organ-specific androgen-independent pathway of progression in patients with metastatic prostate cancer. Urologic Oncology 1(2):67-72, 1995. e-Pub 1995. PMID: 21224094.
370. Abdul, M, J-T H, Logothetis CJ, Hoosein NM. Secretion of prostate-specific antigen-suppressing activity by two human prostate carcinoma cell lines. Urologic Oncology 1(1):38-41, 1995. e-Pub 1995. PMID: 21224088.
371. Sella A, Aggarwal BB, Kilbourn RG, Bui CA, Zukiwski AA, Logothetis CJ. Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancer. Cancer Biother 10(3):225-35, 1995. e-Pub 1995. PMID: 8547961.
372. Logothetis CJ, Hossan EA, Smith TL. SMS 201-995 in the treatment of refractory prostatic carcinoma. Anticancer Res 14(6B):2731-4, 1994. e-Pub 1994. PMID: 7872709.
373. Mitropoulos D, Dimopoulos MA, Kiroudi-Voulgari A, Zervas A, Dimopoulos C, Logothetis CJ. Neoadjuvant cisplatin and interferon-alpha 2B in the treatment and organ preservation of penile carcinoma. J Urol 152(4):1124-6, 1994. e-Pub 1994. PMID: 8072080.
374. Ellerhorst JA, Kilbourn RG, Amato RJ, Zukiwski AA, Jones E, Logothetis CJ. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma. J Urol 152(3):841-5, 1994. e-Pub 1994. PMID: 8051732.
375. Logothetis CJ, Hossan E, Recondo G, Sella A, Ellerhorst J, Kilbourn R, Zukiwski A, Amato R. 5-Fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: an effective regimen. Anticancer Res 14(3B):1265-9, 1994. e-Pub 1994. PMID: 8067694.
376. Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 14(3A):1215-20, 1994. e-Pub 1994. PMID: 8074475.
377. Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12(4):683-8, 1994. e-Pub 1994. PMID: 7512126.
378. Dimopoulos MA, Finn L, Logothetis CJ. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. J Urol 151(3):598-600; discussion 600-1, 1994. e-Pub 1994. PMID: 8308966.
379. Sella A, Kilbourn RG, Gray I, Finn L, Zukiwski AA, Ellerhorst J, Amato RJ, Logothetis CJ. Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother 9(2):103-11, 1994. e-Pub 1994. PMID: 7812360.
380. Hoosein NM, Logothetis CJ, Chung LW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 149(5):1209-13, 1993. e-Pub 1993. PMID: 8097794.
381. Dimopoulos MA, Logothetis CJ, Markowitz A, Sella A, Amato R, Ro J. Collecting duct carcinoma of the kidney. Br J Urol 71(4):388-91, 1993. e-Pub 1993. PMID: 8499979.
382. Sella A, Swanson DA, Ro JY, Putnam JB, Jr, Amato RJ, Markowitz AB, Logothetis CJ. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol 149(1):19-21; discussion 21-2, 1993. e-Pub 1993. PMID: 8417208.
383. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52(24):6940-4, 1992. e-Pub 1992. PMID: 1458483.
384. Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N, Benedict WF. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84(16):1256-61, 1992. e-Pub 1992. PMID: 1640485.
385. Sella A, Logothetis CJ, Fitz K, Dexeus FH, Amato R, Kilbourn R, Wallace S. Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. J Urol 147(3):573-7, 1992. e-Pub 1992. PMID: 1538431.
386. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 147(3):935-7, 1992. e-Pub 1992. PMID: 1311396.
387. Giralt SA, Dexeus F, Amato R, Sella A, Logothetis C. Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic gonadotropin. Cancer 69(5):1286-90, 1992. e-Pub 1992. PMID: 1371235.
388. Grignon DJ, Ro JY, Ayala AG, Shum DT, Ordonez NG, Logothetis CJ, Johnson DE, Mackay B. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases. Cancer 69(2):527-36, 1992. e-Pub 1992. PMID: 1309435.
389. Sella, A, Amato RJ, Fitz K, Kilbourn RG, Logothetis, CJ. Interferon-alpha and 5-fluorouracil Combination Chemotherapy for Metastatic Renal Cell Cancer. Inter and Cyto 20, 1992. e-Pub 1992. PMID: 1538431.
390. Wishnow KI, Levinson AK, Johnson DE, Tenney DM, Grignon DJ, Ro JY, Ayala AJ, Logothetis CJ, Swanson DA, Babaian RJ, et al. Stage B (P2/3A/N0) transitional cell carcinoma of bladder highly curable by radical cystectomy. Urology 39(1):12-6, 1992. e-Pub 1992. PMID: 1728789.
391. Logothetis CJ. Chemotherapy resistant transitional cell carcinoma as a target for chemoprevention. J Cell Biochem Suppl 16I:128-31, 1992. e-Pub 1992. PMID: 1305675.
392. Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Fitz K, Striegel A. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol 146(5):1284-7, 1991. e-Pub 1991. PMID: 1719241.
393. Sella A, el Naggar A, Ro JY, Dexeus FH, Amato RJ, Lee JS, Finn L, Logothetis CJ. Evidence of malignant features in histologically mature teratoma. J Urol 146(4):1025-8, 1991. e-Pub 1991. PMID: 1680200.
394. Dimopoulos MA, Amato RJ, Logothetis CJ. Predictive factors for effective salvage therapy of nonseminomatous germ cell tumors of testis. Urology 38(4):351-4, 1991. e-Pub 1991. PMID: 1661457.
395. Logothetis CJ. Organ preservation in bladder carcinoma: a matter of selection. J Clin Oncol 9(9):1525-6, 1991. e-Pub 1991. PMID: 1875215.
396. Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Ogden S, Striegel A, Kwan J, Newman RA. Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol 146(3):709-13, 1991. e-Pub 1991. PMID: 1831513.
397. Dexeus FH, Logothetis CJ, Sella A, Fitz K, Striegel A, Amato RJ, Liu FJ. Serum biomarkers in metastatic renal cell carcinoma. Urology 38(1):6-10, 1991. e-Pub 1991. PMID: 1714107.
398. Sella A, Logothetis CJ, Dexeus FH, Amato R, Finn L, Fitz K. Cisplatin combination chemotherapy for elderly patients with urothelial tumours. Br J Urol 67(6):603-7, 1991. e-Pub 1991. PMID: 2070205.
399. Logothetis CJ, Hossan E, Sella A, Dexeus FH, Amato RJ. Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst 83(4):285-8, 1991. e-Pub 1991. PMID: 1994058.
400. Sella A, Logothetis CJ, Dexeus FH, Amato R. Chemotherapy immediately after surgery for patients with germ cell tumors. Urology 36(3):264-6, 1990. e-Pub 1990. PMID: 2168105.
401. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8(6):1050-5, 1990. e-Pub 1990. PMID: 2189954.
402. Logothetis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst 82(8):667-72, 1990. e-Pub 1990. PMID: 2181151.
403. Dexeus FH, Logothetis CJ, Sella A, Fitz K, Amato R, Reuben JM, Dozier N. Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. J Clin Oncol 8(2):325-9, 1990. e-Pub 1990. PMID: 2137163.
404. Logothetis CJ, Chong C, Dexeus FH, Sella A, Ogden S. Intensive chemotherapy for metastatic nonseminomatous germ cell tumors. Prog Clin Biol Res 350:301-7, 1990. e-Pub 1990. PMID: 1696741.
405. Logothetis CJ, Dexeus FH, Chong C, Sella A, Ogden S. The impact of chemotherapy on the survival of patients with metastatic urothelial tumors. Prog Clin Biol Res 350:107-14, 1990. e-Pub 1990. PMID: 2201037.
406. Dexeus FH, Logothetis CJ, Sella A, Finn L. Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma. Am J Clin Oncol 12(4):350-4, 1989. e-Pub 1989. PMID: 2667326.
407. Sella A, Dexeus FH, Chong C, Ro JY, Logothetis CJ. Radiation therapy-associated invasive bladder tumors. Urology 33(3):185-8, 1989. e-Pub 1989. PMID: 2919477.
408. Dexeus FH, Shirkhoda A, Logothetis CJ, Chong C, Sella A, Ogden S, Swanson D. Clinical and radiological correlation of retroperitoneal metastasis from nonseminomatous testicular cancer treated with chemotherapy. Eur J Cancer Clin Oncol 25(1):35-43, 1989. e-Pub 1989. PMID: 2920767.
409. Logothetis CJ, Dexeus FH, Chong C, Sella A, Ayala AG, Ro JY, Pilat S. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J Urol 141(1):33-7, 1989. e-Pub 1989. PMID: 2908950.
410. Shirkhoda A, Dexeus FH, Logothetis CJ. Clinical and radiologic staging of locally advanced and inoperable bladder carcinoma. J Comput Tomogr 12(4):298-302, 1988. e-Pub 1988. PMID: 3197433.
411. Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S, Smith T, Swanson DA, Babaian RJ, Wishnow KI, et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 6(10):1590-6, 1988. e-Pub 1988. PMID: 3171626.
412. Dunphy CH, Ayala AG, Swanson DA, Ro JY, Logothetis C. Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone. Cancer 62(6):1202-6, 1988. e-Pub 1988. PMID: 2842034.
413. Chong CD, Logothetis CJ, Savaraj N, Fritsche HA, Gietner AM, Samuels ML. The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. J Clin Pharmacol 28(8):714-8, 1988. e-Pub 1988. PMID: 3216038.
414. Dexeus FH, Logothetis CJ, Chong C, Sella A, Ogden S. Genetic abnormalities in men with germ cell tumors. J Urol 140(1):80-4, 1988. e-Pub 1988. PMID: 2837589.
415. Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Ogden S, von Eschenbach A, Ayala A. Adjuvant chemotherapy of bladder cancer: a preliminary report. J Urol 139(6):1207-11, 1988. e-Pub 1988. PMID: 3373589.
416. Chong CD, Logothetis CJ, von Eschenbach AC, Ayala AG, Samuels ML. Successful treatment of pure endodermal sinus tumors in adult men. J Clin Oncol 6(2):303-7, 1988. e-Pub 1988. PMID: 2448426.
417. Logothetis CJ, Samuels ML, Ogden SL, Dexeus FH, Chong CD. Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term followup in 52 patients. J Urol 138(4):789-94, 1987. e-Pub 1987. PMID: 3656535.
418. Sella A, Logothetis CJ, Ro JY, Swanson DA, Samuels ML. Sarcomatoid renal cell carcinoma. A treatable entity. Cancer 60(6):1313-8, 1987. e-Pub 1987. PMID: 2441841.
419. Logothetis CJ, Swanson DA, Dexeus F, Chong C, Ogden S, Ayala AG, von Eschenbach AC, Johnson DE, Samuels ML. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. J Clin Oncol 5(6):906-11, 1987. e-Pub 1987. PMID: 2438389.
420. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 59(10):1803-9, 1987. e-Pub 1987. PMID: 3030528.
421. Chong C, Logothetis CJ, von Eschenbach A, Ayala A, Samuels M. Orchiectomy in advanced germ cell cancer following intensive chemotherapy: a comparison of systemic to testicular response. J Urol 136(6):1221-3, 1986. e-Pub 1986. PMID: 3022018.
422. Dexeus FH, Logothetis C, Samuels ML, Hossan B. Phase II study of spirogermanium in metastatic prostate cancer. Cancer Treat Rep 70(9):1129-30, 1986. e-Pub 1986. PMID: 3742495.
423. Dexeus F, Logothetis C, Hossan E, Samuels ML. Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies. J Urol 136(2):403-7, 1986. e-Pub 1986. PMID: 2426474.
424. Logothetis CJ, Samuels ML, Selig DE, Ogden S, Dexeus F, Swanson D, Johnson D, von Eschenbach A. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. Am J Med 81(2):219-28, 1986. e-Pub 1986. PMID: 2426944.
425. Logothetis CJ, Samuels ML, Selig DE, Johnson DE, Swanson DA, von Eschenbach AC. Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report. J Urol 134(6):1127-30, 1985. e-Pub 1985. PMID: 2414470.
426. Logothetis CJ, Samuels ML, Ogden S, Dexeus FH, Swanson D, Johnson DE, von Eschenbach A. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol 134(3):460-4, 1985. e-Pub 1985. PMID: 2993671.
427. Logothetis CJ, Samuels ML, Ogden S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. Urology 26(3):252-5, 1985. e-Pub 1985. PMID: 3929441.
428. Dexeus F, Logothetis CJ, Samuels ML, Hossan E, von Eschenbach AC. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 69(7-8):885-6, 1985. e-Pub 1985. PMID: 4016795.
429. Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol 3(3):326-35, 1985. e-Pub 1985. PMID: 2579213.
430. Logothetis CJ, Samuels ML, Selig DE, Dexeus FH, Johnson DE, Swanson DA, von Eschenbach AC. Chemotherapy of extragonadal germ cell tumors. J Clin Oncol 3(3):316-25, 1985. e-Pub 1985. PMID: 2579212.
431. Logothetis CJ. Perioperative chemotherapy for the management of primary local regional urothelial tumors. Prog Clin Biol Res 201:359-66, 1985. e-Pub 1985. PMID: 3841594.
432. Logothetis CJ, Samuels ML, Selig DE, Wallace S, Johnson DE. Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumors. Cancer Treat Rep 69(1):33-8, 1985. e-Pub 1985. PMID: 2981619.
433. Logothetis CJ. Preoperative chemotherapy in the treatment of germinal tumors. Prog Clin Biol Res 201:341-50, 1985. e-Pub 1985. PMID: 2419920.
434. Logothetis CJ, Samuels ML. Surgery in the management of stage III germinal cell tumors. Observations on the M.D. Anderson Hospital experience, 1971-1979. Cancer Treat Rev 11(1):27-37, 1984. e-Pub 1984. PMID: 6203643.
435. Logothetis CJ, Samuels ML, Trindade A, Grant C, Gomez L, Ayala A. The prognostic significance of endodermal sinus tumor histology among patients treated for stage III nonseminomatous germ cell tumors of the testes. Cancer 53(1):122-8, 1984. e-Pub 1984. PMID: 6317156.
436. Logothetis CJ, Samuels ML, von Eschenbach AC, Trindade A, Ogden S, Grant C, Johnson DE. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1(6):368-79, 1983. e-Pub 1983. PMID: 6422006.
437. Bracken RB, Johnson DE, Frazier OH, Logothetis CJ, Trindade A, Samuels ML. The role of surgery following chemotherapy in stage III germ cell neoplasms. J Urol 129(1):39-43, 1983. e-Pub 1983. PMID: 6298475.
438. Logothetis CJ, Samuels ML, Wallace S, Chuang V, Trindade A, Grant C, Haynie TP, rd, Johnson DE. Management of pelvic complications of malignant urothelial tumors with combined intra-arterial and iv chemotherapy. Cancer Treat Rep 66(7):1501-7, 1982. e-Pub 1982. PMID: 7046931.
439. Logothetis CJ, von Eschenbach AC, Samuels ML, Trindade A, Johnson DE. Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report. Cancer Treat Rep 66(1):57-63, 1982. e-Pub 1982. PMID: 7053267.
440. Logothetis CJ, Samuels ML, Trindade A. The management of brain metastases in germ cell tumors. Cancer 49(1):12-8, 1982. e-Pub 1982. PMID: 6274499.
441. Trindade A, Samuels ML, Logothetis CJ. Chemotherapy of carcinoma of renal pelvis: preliminary report. Urology 18(1):54-9, 1981. e-Pub 1981. PMID: 6894814.

Invited Articles

1. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26(8):1589-604, 2015. e-Pub 2015. PMID: 26041764.
2. Chan CH, Jo U, Kohrman A, Rezaeian AH, Chou PC, Logothetis C, Lin HK. Posttranslational regulation of Akt in human cancer. Cell Biosci 4(1):59, 2014. e-Pub 2014. PMID: 25309720.
3. Sharma P, Logothetis C. Prostate cancer: Combination of vaccine plus ipilimumab-safety and toxicity. Nat Rev Urol 9(6):302-3. e-Pub 2012. PMID: 22565371.
4. Logothetis CJ, Efstathiou E, Manuguid F, Kirkpatrick P. Abiraterone acetate. Nat Rev Drug Discov 10(8):573-4, 2011. e-Pub 2011. PMID: 21804589.
5. Logothetis CJ. When 'dueling technologies' are mistaken for progress. BJU Int 107(11):1699-700, 2011. e-Pub 2011. PMID: 21592278.
6. Efstathiou E, Logothetis CJ. Prostate cancer: Thalidomide for prostate cancer: is there progress?. Nat Rev Urol 6(5):248-50, 2009. e-Pub 2009. PMID: 19424170.
7. Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA, Logothetis CJ. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 26(36):5936-42, 2008. e-Pub 2008. PMID: 19029421.
8. Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA, Walsh PC, Cancer Nerwork NC. Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 5(7):650-83, 2007. e-Pub 2007. PMID: 17692170.
9. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J, Cancer Network NC. Kidney cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4(10):1072-81, 2006. e-Pub 2006. PMID: 17112454.
10. Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw 4(10):1059-70, 2006. e-Pub 2006. PMID: 17112453.
11. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5(1):21-8, 2005. e-Pub 2005. PMID: 15630412.
12. Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pili R, Pohar KS, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA, Cancer Network NC. Kidney cancer. Clinical practice guidelines. J Natl Compr Canc Netw 3(1):84-93, 2005. e-Pub 2005. PMID: 19813325.
13. Motzer RJ, Bahnson RR, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA, Cancer Network NC. Testicular cancer. Clinical practice guidelines. J Natl Compr Canc Netw 3(1):52-76, 2005. e-Pub 2005. PMID: 19813323.
14. Logothetis CJ. The case for a biologically based classification of prostate cancer. Semin Oncol 30(5):562-6, 2003. e-Pub 2003. PMID: 14571406.
15. Tu SM, Lin SH, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol 3(8):508-13, 2002. e-Pub 2002. PMID: 12147437.
16. Logothetis C, Millikan R. Docetaxel in the management of advanced or metastatic urothelial tract cancer. Oncology (Williston Park) 16(6 Suppl 6):107-11, 2002. e-Pub 2002. PMID: 12108893.
17. Logothetis CJ. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology (Williston Park) 16(6 Suppl 6):63-72, 2002. e-Pub 2002. PMID: 12108899.
18. Logothetis CJ. A Framework for Rational and Accelerated Development of Therapy for Prostate Cancer. Principles and Practice of Oncology 16(6), 2002. e-Pub 2002.
19. Merritt JA, Roth JA, Logothetis CJ. Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin Oncol 28(5 Suppl 16):105-14, 2001. e-Pub 2001. PMID: 11706402.
20. Logothetis CJ. Docetaxel in the Treatment of Prostate Cancer: Opportunities for Combination Regimens and Challenges to Development. . Seminars in Oncology 28(4):Supplement N, 2001. e-Pub 2001.
21. Bahnson RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel M, Lange PH, Logothetis C, Pow-Sang JM, Roach M, rd, Sandler H, Scardino PT, Taylor RJ, Urban DA, Walsh PC, Wilson TG. NCCN Practice Guidelines for Prostate Cancer. Oncology (Williston Park) 14(11A):111-9, 2000. e-Pub 2000. PMID: 11195405.
22. Kim J, Logothetis CJ. Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Urol Clin North Am 26(2):281-90, 1999. e-Pub 1999. PMID: 10361551.
23. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev 17(4):361-71, 1998. e-Pub 1998. PMID: 10453280.
24. Gjertsen BT, Logothetis CJ, McDonnell TJ. Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer Metastasis Rev 17(4):345-51, 1998. e-Pub 1998. PMID: 10453278.
25. Corral DA, Logothetis CJ. New approaches in the treatment of metastatic transitional-cell cancer of the bladder. World J Urol 15(2):139-43, 1997. e-Pub 1997. PMID: 9144905.
26. Baker LH, Hanks G, Gershenson D, Kantoff P, Lange P, Logothetis C, Sandler H, Walsh P. NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 10(11 Suppl):265-88, 1996. e-Pub 1996. PMID: 8953609.
27. Tu, S, Jones D, Finn L, Amato R, Ellerhorst J, Kilbourn R, Logothetis CJ. Strontium-89 (Str-89) combined with adriamycin (Adr) in the treatment of patients (pts) with androgen-independent prostate carcinoma (AI PCa), 1995. e-Pub 1995.
28. Logothetis CJ. Chemotherapeutic approaches in advanced prostate cancer. Oncology (Supplement) 8(11):15-18, 1994. e-Pub 1994.
29. Logothetis CJ, Amato RJ. Management of Residual Mass Following Effective Therapy for Seminoma, 1993. e-Pub 1993.
30. Logothetis C. Treatment of chemotherapy-refractory metastatic urothelial tumors. Urol Clin North Am 19(4):775-7, 1992. e-Pub 1992. PMID: 1441031.
31. Logothetis C, Hoosein N. The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma. J Cell Biochem Suppl 16H:128-34, 1992. e-Pub 1992. PMID: 1337763.
32. Logothetis CJ. The role of chemotherapy in the management of urothelial tumors: Interpretation of the M. D. Anderson Cancer Center results. World Journal of Urology 6(3):163-166, 1988. e-Pub 1988.
33. Logothetis CJ. Choriocarcinoma syndrome. Cancer Bulletin 36(2):118-120, 1984. e-Pub 1984.
34. Logothetis CJ, Samuels M. Intra-arterial chemotherapy for malignant urothelial tumors. Cancer Bulletin 36(1):47-52, 1984. e-Pub 1984.
35. Logothetis CJ. The lymphoma that wasn’t. World Journal of Urology 2:73-75, 1984. e-Pub 1984.
36. Logothetis, CJ, von Eschenbach A, Samuels ML, Trindade A, Johnson DE. DMF regimen for hormone-refractory adenocarcinoma of the prostate - The first 42 patients. Cancer Bulletin 34(1):26-28, 1982. e-Pub 1982.
37. Logothetis CJ. CISCA Chemotherapy for bladder cancer. Cancer Bulletin 33(2):79-80, 1981. e-Pub 1981.

Other Articles

1. Logotheti S, Papadaki E, Zolota V, Logothetis C, Vrahatis AG, Soundararajan R, Tzelepi V Lineage Plasticity and Stemness Phenotypes in Prostate Cancer: Harnessing the Power of Integrated "Omics" Approaches to Explore Measurable Metrics. Cancers (Basel) 15(17), 2023. PMID: 37686633.
2. Hussain A, Tripathi A, Pieczonka C, Cope D, McNatty A, Logothetis C, Guise T Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 24(2):290-300, 2021. PMID: 33028943.
3. Labanca E, Vazquez ES, Corn PG, Roberts JM, Wang F, Logothetis CJ, Navone NM Fibroblast growth factors signaling in bone metastasis. Endocr Relat Cancer 27(7):R255-R265, 2020. PMID: 32369771.
4. Dutta P, Salzillo TC, Pudakalakatti S, Gammon ST, Kaipparettu BA, McAllister F, Wagner S, Frigo DE, Logothetis CJ, Zacharias NM, Bhattacharya PK Assessing Therapeutic Efficacy in Real-time by Hyperpolarized Magnetic Resonance Metabolic Imaging. Cells 8(4), 2019. PMID: 30978984.
5. Tosco L, Briganti A, D'amico AV, Eastham J, Eisenberger M, Gleave M, Haustermans K, Logothetis CJ, Saad F, Sweeney C, Taplin ME, Fizazi K Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. Eur Urol 75(1):44-60, 2019. PMID: 30286948.
6. Logothetis C, Aparicio A, Thompson TC ER stress in prostate cancer: A therapeutically exploitable vulnerability?. Sci Transl Med 10(439), 2018. PMID: 29720450.
7. Logothetis C, Morris MJ, Den R, Coleman RE Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev 37(1):189-196, 2018. PMID: 29380085.
8. Soundararajan R, Aparicio AM, Logothetis CJ, Mani SA, Maity SN Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol 8:69, 2018. PMID: 29600194.
9. Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. Eur Urol 68(5):850-8, 2015. PMID: 26153564.
10. Araujo J, Logothetis C Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev 36(6):492-500, 2010. PMID: 20226597.
11. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 23(32):8232-41, 2005. PMID: 16278478.
12. Papandreou CN, Logothetis CJ Bortezomib as a potential treatment for prostate cancer. Cancer Res 64(15):5036-43, 2004. PMID: 15289299.
13. Mathew P, Fidler IJ, Logothetis CJ Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol 31:24-9, 2004. PMID: 15176001.
14. Logothetis CJ Foundation for the integration of biologically based therapy in the management of prostate cancer. Prostate 57(1):32-8, 2003. PMID: 12886521.
15. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7(5):1198-203, 2001. PMID: 11350884.
16. Logothetis CJ Biologic foundation of the therapy for advanced germ cell tumors. Semin Urol Oncol 16(2):62-4, 1998. PMID: 9649228.
17. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3(12 Pt 1):2493-500, 1997. PMID: 9815652.
18. Sternberg CN, Raghaven D, Ohi Y, Bajorin D, Herr H, Kato T, Kuroda M, Logothetis CH, Scher H, Splinter TA Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?. Int J Urol 2(2):76-88, 1995. PMID: 7553308.
19. Kilbourn RG, Fonseca GA, Griffith OW, Ewer M, Price K, Striegel A, Jones E, Logothetis CJ NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit Care Med 23(6):1018-24, 1995. PMID: 7774211.
20. Fornage BD, Logothetis CJ, Swanson DA, Ro JY Bilateral testicular metastases from prostate carcinoma: gray-scale and color Doppler sonographic findings. J Ultrasound Med 14(3):247-9, 1995. PMID: 7760471.
21. Crawford ED, Kozlowski JM, Debruyne FM, Fair WR, Logothetis CJ, Balmer C, Robinson RG, Porter AT, Kirk D The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. Urology 44(4):481-5, 1994. PMID: 7524233.
22. Logothetis CJ, Hoosein NM, Hsieh JT The clinical and biological study of androgen independent prostate cancer (AI PCa). Semin Oncol 21(5):620-9, 1994. PMID: 7524155.
23. Chung LW, Li W, Gleave ME, Hsieh JT, Wu HC, Sikes RA, Zhau HE, Bandyk MG, Logothetis CJ, Rubin JS, et al Human prostate cancer model: roles of growth factors and extracellular matrices. J Cell Biochem Suppl 16H:99-105, 1992. PMID: 1289680.
24. Dexeus FH, Kilbourn R, Chong C, Logothetis CJ, Sella A, Grignon D Association of germ cell tumors and Hodgkin's disease. Urology 37(2):129-34, 1991. PMID: 1846990.
25. Gutterman J, Vadhan-Raj S, Logothetis C, Anaissle E, Estey E, Talpaz M, Kurzrock R Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense. Semin Hematol 27(3):15-24, 1990. PMID: 2198660.
26. Logothetis CJ The case for relevant staging of germ cell tumors. Cancer 65(3):709-17, 1990. PMID: 2154316.
27. Tetu B, Ro JY, Ayala AG, Ordonez NG, Logothetis CJ, von Eschenbach AC Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome. Urology 33(2):148-52, 1989. PMID: 2536972.
28. Floyd C, Ayala AG, Logothetis CJ, Silva EG Spermatocytic seminoma with associated sarcoma of the testis. Cancer 61(2):409-14, 1988. PMID: 3334976.
29. Dexeus FH, Logothetis CJ, Samuels ML, Ayala AG, Hossan E Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimens. J Urol 137(1):122-5, 1987. PMID: 3795354.
30. Logothetis CJ, Newell GR, Samuels ML Testicular cancer in homosexual men with cellular immune deficiency: report of 2 cases. J Urol 133(3):484-6, 1985. PMID: 2579253.
31. Rusch VW, Logothetis C, Samuels M Endodermal sinus tumor of the mediastinum. Report of apparent cure in two patients with extensive disease. Chest 86(5):745-7, 1984. PMID: 6207993.
32. Libshitz HI, Jing BS, Wallace S, Logothetis CJ Sterilized metastases: a diagnostic and therapeutic dilemma. AJR Am J Roentgenol 140(1):15-9, 1983. PMID: 6600307.
33. Logothetis CJ, Samuels ML, Trindade A, Johnson DE The growing teratoma syndrome. Cancer 50(8):1629-35, 1982. PMID: 6288220.

Editorials

1. Logothetis, CJ, Pilie, PG. Putting Precision Medicine in Prostate Cancer into Practice. European urology 83(2):121-124, 2023.
2. Logothetis CJ, Aparicio A, Koinis F, Corn PG, Efstathiou E. Prostate Cancer: Quo Vadis?. Eur Urol 76(6):709-711, 2019. PMID: 31300238.
3. Logothetis CJ. Improved Outcomes in Men with Advanced Prostate Cancer. N Engl J Med 377(4):388-390, 2017. PMID: 28745978.
4. Logothetis CJ, Aparicio AM. Is It Time to Re-Examine the Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases?. J Clin Oncol 34(24):2810-1, 2016. PMID: 27432923.
5. Logothetis CJ. Prostate cancer bone metastases: not so systemic after all. Lancet Oncol 15(7):675-6, 2014. PMID: 24836275.
6. Logothetis CJ. Treatment of castrate-resistant prostate cancer. J Urol 190(2):439-40, 2013. PMID: 23707438.
7. Logothetis CJ. Re: intratumor heterogeneity and branched evolution revealed by multiregion sequencing. Eur Urol 64(1):170, 2013. PMID: 23746321.
8. Logothetis CJ. Treatment of prostate cancer metastases: more than semantics. Lancet 379(9810):4-6, 2012. PMID: 22093188.
9. Kim J, Amos CI, Logothetis C. 5α-Reductase inhibitors for prostate-cancer prevention. N Engl J Med 365(24):2340, 2011. PMID: 22168662.
10. Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov 1(6):466-8, 2011. PMID: 22586648.
11. Logothetis CJ, Siefker-Radtke A. Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Eur Urol 57(4):728-9, 2010. PMID: 20965043.
12. Efstathiou E, Kim J, Logothetis CJ. Informative clinical investigation: a demanding taskmaster. J Clin Oncol 27(30):4937-8, 2009. PMID: 19720892.
13. Logothetis CJ, Schellhammer PF. High-grade prostate cancer and the prostate cancer prevention trial. Cancer Prev Res (Phila Pa) 1(3):151-2, 2008. PMID: 19138948.
14. Logothetis CJ, Millikan R. Chemotherapy for advanced prostate cancer: 25 years later. J Clin Oncol 26(15):2423-4, 2008. PMID: 18487561.
15. Fizazi K, Chen I, Logothetis CJ. Germ-cell tumor survivors: the price for cure. Ann Oncol 13(2):187-9, 2002. PMID: 11885993.

Abstracts

1. Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer, 2018. e-Pub 2018. PMID: 29138344.
2. Higano CS, Zimberg SH, Dizdarevic S, Harshman LC, Logue J, Baldari S, Richardson T, Bottomley DM, Schostak M, Tombal BF, Sade JP, Miller K, Logothetis C, Bellmunt J, Smith MR, Saad F, Muenz-Wollny R, Sanctis YD, Sartor A, Sternberg CN. Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study. ASCO, 2017. e-Pub 2017.
3. Aparicio A, Xiao L, Ning Tapia EL, Hoang A, Ramesh N, Wu W, Chancoco H, Heath EI, Efstathiou E, Thompson TC, Troncoso P, Broom BM, Zurita AJ, Navin N, Logothetis C, Corn PG. The aggressive variant prostate carcinoma (AVPC) molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC). ASCO, 2017. e-Pub 2017.
4. Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu C, Gao J, Vence LM, Blando JM, Corn PG, Araujo JC, Zurita AJ, Prokhorova IN, Alstine MV, Logothetis C, Futreal A, Allison JP, Sharma P. Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). ASCO, 2017. e-Pub 2017.
5. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis C, Wistuba II, Wargo JA, Blando JM, Sepulveda MA, Sun JJ, Sharma P. Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer. ASCO, 2017. e-Pub 2017.
6. Corn PG, Zurita AJ, Subudhi SK, Tu S, Aparicio A, Araujo JC, Kim J, Wang J, Efstathiou E, Pagliaro LC, Logothetis C. Cabozantinib plus androgen deprivation therapy in patients with androgen-dependent metastatic prostate cancer. Genitourinary Cancers Symposium, 2017. e-Pub 2017.
7. Luo J, Attard, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting, 2017. e-Pub 2017. PMID: 29258679.
8. Efstathiou E, Tsikkinis A, Wen S, Li Ning Tapia E, Hoang A, Aparicio A, S-M T, Rangel G, Troncoso P, Corn P, Araujo J, Logothetis C. Abiraterone acetate (AA) followed by randomization to dasatinib (D) or sunitinib malate (S) in metastatic castrate resistant prostate cancer (mCRPC). ESMO, 2016. e-Pub 2016.
9. Corn PG, Ning Tapia EL, Xiao L, Heath EI, Chancoco H, Hoang A, Efstathiou E, Thompson TC, Troncoso P, Logothetis C, Aparicio A. Confirmatory analysis to determine associations between platinum-sensitivity, molecular signature of combined tumor suppressor defects and aggressive variant prostate carcinomas (AVPC). ASCO, 2016. e-Pub 2016.
10. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Achim MF, Wang X, Choi S, Kuban DA, Troncoso P, Logothetis C, Thompson TC, Kim J. Plasma caveolin-1 to predict disease reclassification in men with early stage prostate cancer in active surveillance. ASCO, 2016. e-Pub 2016.
11. Efstathiou E, Davis JW, Titus MA, Chapin BF, Zurita AJ, Wen S, Ning Tapia EML, Hoang A, Corn PG, Wang X, Whittington F, Troncoso P, Logothetis C. Neoadjuvant enzalutamide (ENZA) and abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus AA+ LHRHa in localized high-risk prostate cancer (LHRPC). ASCO, 2016. e-Pub 2016.
12. Zurita AJ, Carlsson A, Luttgen MS, Bethel K, Troncoso P, Corn PG, Kolatkar A, Hicks JB, Logothetis C, Kuhn P. A clinically applicable strategy to concurrently profile prostate cancer (PCa) in circulation and bone using high-definition single cell analysis (HD-SCA). ASCO, 2016. e-Pub 2016.
13. Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu C, Vence LM, Logothetis C, Futreal A, Allison JP, Sharma P. A feasibility study to determine T cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC). ASCO, 2016. e-Pub 2016.
14. Fizazi K, Flechon A, Le Teuff G/, Mardiak J, Pagliaro LC, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard J, Malhaire J, Linassier C, Habibian M, Reckova M, Logothetis C, Culine S. Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT). ASCO, 2016. e-Pub 2016.
15. Efstathiou E, Li W, Gormley M, McMullin R, Ricci DS, Davis JW, Ning Tapia EML, Troncoso P, Titus MA, Hoang A, Wen S, Zurita AJ, Tran N, Peng W, Kheoh T, Molina A, Logothetis C. Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa. ASCO, 2015. e-Pub 2015.
16. Corn PG, Tu S, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Heath EI, Logothetis C, Aparicio A. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). ASCO, 2015. e-Pub 2015.
17. Efstathiou E, Troncoso P, Ning Tapia EL, Davis JW, Titus MA, Hoang A, Prokhorova IN, Wen S, Logothetis C. Effects of preoperative abiraterone acetate (AA) plus enzalutamide (E) and leuprolide acetate (LHRHa) versus AA and LHRHa in localized high-risk prostate cancer (LHRPC). ASCO, 2015. e-Pub 2015.
18. Aparicio A, Shen L, Ning Tapia EL, Lu J, Chen H, Zhang J, Wu G, Wang X, Troncoso P, Corn PG, Thompson TC, Broom BM, Baggerly KA, Logothetis C, Maity SN. Molecular characterization of clinically defined aggressive variant prostate cancer (AVPCa) in prospectively collected tissues and corresponding patient derived xenografts (PDX). ASCO, 2015. e-Pub 2015.
19. Chapin BF, Mcguire SE, Wang X, Troncoso P, Davis JW, Navai N, Subudhi SK, Zurita AJ, Araujo JC, Pettaway CA, Matin SF, Pisters LL, Ward JF, Tu S, Wang J, Le O, Logothetis C, Aparicio A. A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer. ASCO, 2015. e-Pub 2015.
20. Dondossola E, Alexander S, Alexander S, Holzapfel B, Logothetis C, Hutmacher D, Friedl AP. Preclinical monitoring of prostate cancer lesions in bone by intravital multiphoton microscopy. AACR, 2015. e-Pub 2015.
21. Labanca E, Wan X, Yang J, Iyer M, Logothetis C, Chinnaiyan A, Navone AN. Fibroblast growth factor receptor 1 isoforms in prostate cancer bone metastases. AACR, 2015. e-Pub 2015.
22. Bagheri-Yarmand R, Lahiri S, Wan X, Navone N, Logothetis CJ, Gagel RF, M Sinha AK. A novel epigenetic regulator histone demethylase NO66 promotes prostate cancer bone metastasis. AACR, 2015. e-Pub 2015.
23. Aparicio A, Shen L, Ning Tapia EL, Lu J, Chen H, Zhang J, Wu G, Wang X, Troncoso P, Broom BM, Baggerly KA, Logothetis C, Maity SN. A comprehensive molecular characterization of aggressive variant prostate cancer (PC). Genitourinary Cancers Symposium, 2015. e-Pub 2015.
24. Maity SN, Wu G, Lu J, Hoang A, Landesman Y, McCauley D, Carlson R, Rashal T, Shacham S, Broom BM, Baggerly KA, Aparicio A, Efstathiou E, Araujo JC, Logothetis C. Effect of selinexor (KPT-330), a novel oral selective inhibitor of nuclear export (SINE), on tumor suppressors and cell cycle proteins in prostate cancer cells and regression of castration-resistant patient-derived xenograft tumor growth. Genitourinary Cancers Symposium, 2015. e-Pub 2015.
25. Ryan CJ, Smith MR, Fizazi K, Saad F, Sternberg CN, Logothetis C, Small EJ, Carles J, Flaig TW, Taplin M, Higano CS, De Souza PL, De Bono JS, Griffin TW, Porre PD, Park YC, Li J, Kheoh TS, Molina A, Rathkopf DE. Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis. Genitourinary Cancers Symposium, 2015. e-Pub 2015.
26. Fizazi K, Drake CJ, Kwon ED, Bossi A, van den Eertwegh AJ, Scher HI, Beer TM, McHenry MB, Liu D, Gerritsen WR, Logothetis C. Updated Overall Survival (OS) From the Phase 3 Trial, CA184-043: Ipilimumab (IPI) vs Placebo (PBO) in Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (MCRPC). ESMO, 2014. e-Pub 2014.
27. Efstathiou E, Li Ning Tapia E, Aparicio A, Tu SM, Wen S, Hoang A, Pagliaro L, Harmon C, Troncoso P, Araujo JC, Logothetis C. Maximal Androgen Depletion with Abiraterone Acetate (AA) Followed By Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies Dasatinib or Sunitinib Malate in Metastatic Castrate Resistant Prostate Cancer (MCRPC). Report on Candidate Predictive Androgen Signaling Signature. ESMO, 2014. e-Pub 2014.
28. Logothetis C, Gallick GE, Lin S, Navone AN. The role of bone microenvironment in the lethal progression of prostate cancer. AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment, 2014. e-Pub 2014.
29. Ricci DS, Li W, Griffin TW, Gormley M, Henitz E, Ryan CJ, De Bono JS, Attard G, den Eertwegh AJV, Schrijvers DL, Gullo JJ, Suttmann H, Carles J, Piulats Rodriguez JM, Jones RJ, Logothetis C, Rathkopf DE, Scher HI, Efstathiou E. Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302. ASCO, 2014. e-Pub 2014.
30. Subudhi SK, Aparicio A, Zurita AJ, Araujo JC, Corn PG, Tu SM, Wang X, Harris DR, Winslow KA, Gao J, Logothetis CJ, Sharma P. Finite androgen deprivation therapy (ADT) plus ipilimumab (IPI) in men with hormon-naive metastatic prostate cancer (HN-MPCa). ESMO, 2014. e-Pub 2014.
31. Yu EY, Saad F, Londhe A, Shore ND, Poppel HV, Rathkopf DE, Smith MR, Logothetis C, De Souza PL, Fizazi K, Mulders PF, Mainwaring PN, Hainsworth JD, Beer TM, North SA, Small EJ, Scher HI, Griffin TW, Yu MK, Ryan CJ. Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. Genitourinary Cancers Symposium, 2014. e-Pub 2014.
32. Davis JW, Achim MF, Ward JF, Pettaway CA, Chapin BF, Wang X, Kuban DA, Frank SJ, Lee A, Pisters LL, Matin SF, Shah JB, Karam JA, Papadopoulos JN, Hoffman KE, Pugh TJ, Choi S, Logothetis C, Troncoso P, Kim J. Active surveillance in phenotypically heterogeneous early-stage prostate cancer. ASCO, 2014. e-Pub 2014.
33. Gu J, He Y, Strom SS, Logothetis CJ, Kim J, Wu X. A genetic variant near KLK3 gene is associated with aggressive prostate cancer and can stratify Gleason score 7 patients. AACR, 2014. e-Pub 2014.
34. Dondossola E, Alexander S, Alexander S, Holzapfel BM, Logothetis CJ, Hutmacher DW, Fried P. A humanized bone model for preclinical monitoring of prostate cancer lesions by intravital multiphoton microscopy. AACR, 2014. e-Pub 2014.
35. Drake CG, Kwon ED, Fizazi K, Bossi A, den Eertwegh AJV, Logothetis C, Scher HI, Beer TM, McHenry B, Liu D, Gerritsen WR. Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium, 2014. e-Pub 2014.
36. Tu S, Bilen MA, Tu ZH, General R, Ward JF, Pisters LL, General R, Chen AH, Nieto Y, Pagliaro LC, Yeung S, Logothetis C, Lin S, Gorlov I. Nonseminomatous germ cell tumor of the testis: Prognostic factors for a lethal phenotype. Genitourinary Cancers Symposium, 2014. e-Pub 2014.
37. Loriot Y, Pagliaro LC, Flechon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Bui B, Gravis G, Eymard J, Malhaire J, Linassier C, Habibian M, Logothetis C, Culine S, Laplanche A, Fizazi K. Patterns of relapse in poor-prognosis germ cell tumors in the GETUG 13 trial: Implications for assessment of brain progression. Genitourinary Cancers Symposium, 2014. e-Pub 2014.
38. Corn PG, Tu S, Zurita AJ, Araujo JC, Pagliaro LC, Logothetis C, Aparicio A. A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features. Genitourinary Cancers Symposium, 2014. e-Pub 2014.
39. Maity SN, Wu G, Lu J, Hoang A, Landesman Y, McCauley D, Shacham S, Kauffman MG, Aparicio AM, Efstathiou E, Araujo JC, Logothetis CJ. Preclinical efficacy of the novel, oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) on castration resistant prostate cancer. AACR, 2014. e-Pub 2014.
40. Zurita AJ, Carlsson A, Luttgen MS, Bethel K, Logothetis CJ, Hicks J, Kuhn P. High-Definition Single Cell Analysis (HD-SCA) of Prostate Cancer (PCa) Cells in Matched Bone Marrow and Blood from Patients. ESMO, 2014. e-Pub 2014.
41. Parker PA, Davis JW, Latini D, Baum G, Wang X, Ward JF, Kuban DA, Frank SJ, Lee A, Logothetis C, Kim J. Associations between uncertainty, anxiety, and quality of life in men with favorable-risk prostate cancer on active surveillance: Two-and-a-half years' follow-up. Genitourinary Cancers Symposium, 2014. e-Pub 2014.
42. Moore WR, Maity SN, Eisner JR, Garvey EP, Hoekstra WJ, Titus MA, Logothetis C, Araujo JC, Efstathiou E, Schotzinger RJ. The enzymology of the selective CYP17 lyase inhibitor, VT-464, and its effects in castration-resistant prostate cancer (CRPC) models. Genitourinary Cancers Symposium, 2014. e-Pub 2014.
43. Efstathiou E, Titus MA, Wen S, SanMiguel A, Hoang A, Haas-Amatsaleh AD, Perabo F, Phung D, Troncoso P, Ouatas T, Logothetis C. Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). ASCO, 2014. e-Pub 2014.
44. Shore, Neal, Rathkopf, Dana, Smith, Matthew R, Bono D, Johann S, Logothetis, Christopher, Souza D, Paul, Fizazi, Karim, Mulders, Peter FA, Mainwaring, Paul, Hainsworth, John D, Beer, Tomasz M, North, Scott, Fradet, Yves, Griffin, Thomas, Park, Youn C, Kheoh, Thian, Small, Eric J, Scher, Howard I, Molina, Arturo, Ryan, Charles J. Efficacy and Long-term Safety Analysis of Study COU-AA-302: Abiraterone Acetate Plus Prednisone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. AUA, 2014. e-Pub 2014.
45. Beer TM, Logothetis C, Gerritsen WR, Kwon ED, Scher HI, Bossi A, den Eertwegh AJV, Drake CG, McHenry B, Liu D, Fizazi K. Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC. Genitourinary Cancers Symposium, 2014. e-Pub 2014.
46. Bilen MA, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin S, Logothetis C, Tu S. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). ASCO, 2014. e-Pub 2014.
47. Kleb BN, Estecio MR, Wu G, Lu J, Logothetis CJ, Maity S, Aparicio AM. Mechanism of androgen receptor (AR) silencing in small cell prostate carcinoma. AACR, 2013. e-Pub 2013.
48. Bilen MA, Lin S, General R, Pagliaro LC, Logothetis C, Gorlov I, Tu S, of Medicine BC, Houston, TX, Cancer Center TUOTMA, Houston, TX. Prediction of a potential lethal phenotype in testicular nonseminomatous germ cell tumor. ASCO, 2013. e-Pub 2013.
49. Richie JP, Montgomery RB, Logothetis CJ, Bubley GJ, Dalkin BL, Sanda MG, Loda MF, Lis RT, True LD, Troncoso P, Genega EM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Haqq CM, Tran N, Peng W, Tamae D, Kheoh T, Molina A, Kantoff PW, Taplin M. Effect of Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate on PSA, Pathologic Response, and Intraprostatic/Serum Androgen Levels in Localized High-Risk Prostate Cancer: Results of a Randomized Phase 2 Study. AUA, 2013. e-Pub 2013.
50. Aparicio AM, Maity S, Wang X, Hoang AG, Efstathiou E, Troncoso P, Logothetis CJ. A molecular characterization of the anaplastic prostate carcinomas. AACR, 2013. e-Pub 2013.
51. Rathkopf DE, Smith MR, De Bono JS, Logothetis C, Shore N, De Souza PL, Fizazi K, Mulders P, Mainwaring PN, Hainsworth JD, Beer TM, North SA, Fradet Y, Griffin TW, Park YC, Kheoh TS, Small EJ, Scher HI, Molina A, Ryan CJ, Cancer Center MS, York N, NY, Cancer Center MGH, Boston, MA, Cancer Research TIO, Foundation Trust TRMN, Sutton, Kingdom U, Cancer Center TUOTMA, Houston, TX, Research Center CU, Beach M, SC, of Medicine UOWSS, Institute I, Liverpool, Australia, Roussy IG, Paris Sud UO, Villejuif, France, Medical Centre RU, Nijmegen, Netherlands, Haematology, of Australia OC, Brisbane, Australia, Research Institute SC, Nashville, TN, Health O, Cancer Institute SUK, Portland, OR, Institute CC, Edmonton, AB, Canada, University L, Québec, QC, Canada, Research J, Development, LLC, Angeles L, CA, Research J, Development, LLC, Raritan, NJ, Cancer Center HDFC, California-San Francisco UO, Francisco S, CA. Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). ASCO, 2013. e-Pub 2013.
52. Maity SN, Wu G, Lu J, Eisner JR, Rafferty SW, Schotzinger RJ, Moore WR, Logothetis CJ, Araujo JC, Efstathiou E. Efficacy of VT-464, a novel selective inhibitor of cytochrome P450 17,20-lyase, in castrate-resistant prostate cancer models. AACR, 2013. e-Pub 2013.
53. Corn PG, Varkaris A, Ning Tapia EML, Araujo JC, Aparicio A, Tu S, Zurita AJ, Efstathiou E, Qiao W, Wen S, Gallick GE, Logothetis C, Cancer Center TUOTMA, Houston, TX, Science Center WVUH, Morgantown, WV. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. Genitourinary Cancers Symposium, 2013. e-Pub 2013.
54. Wan X, Corn P, Yang J, Efstathiou E, Ning Tapia EML, Wang F, McKeehan W, Logothetis C, Troncoso P, Navone NM. Fibroblast growth factor receptor blockade in prostate cancer bone metastases. AACR, 2013. e-Pub 2013.
55. Ryan CJ, Londhe A, Molina A, Smith MR, De Bono JS, Mulders P, Rathkopf DE, Saad F, Logothetis C, Fizazi K, Scher HI, Small EJ, Matheny S, Kheoh TS, Griffin TW, Cancer Center HDFC, California-San Francisco UO, Francisco S, CA, Research J, Development, LLC, Raritan, NJ, Research J, Development, LLC, Angeles L, CA, Cancer Center MGH, Boston, MA, Cancer Research TIO, Foundation Trust TRMN, Sutton, Kingdom U, Medical Centre RU, Nijmegen, Netherlands, Cancer Center MS, York N, NY, Montreal UO, Montreal, QC, Canada, Cancer Center TUOTMA, Houston, TX, Roussy IG, Paris Sud UO, Villejuif, France. Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. ASCO, 2013. e-Pub 2013.
56. Beer TM, Logothetis C, Sharma P, Loriot Y, Fizazi K, Bossi A, Kwon ED, McHenry B, Gagnier P, Gerritsen WR, Health O, Cancer Institute SUK, Portland, OR, Cancer Center TUOTMA, Houston, TX, Roussy IG, Villejuif, France, Clinic M, Rochester, MN, Squibb B, Wallingford, CT, Medical Centre RUN, Nijmegen, Netherlands. CA184-095: A randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC). ASCO, 2013. e-Pub 2013.
57. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Ning Tapia EML, Wang X, Do K, Lee J, Vornik LA, Tangrea J, Parnes HL, Lippman SM, Thompson IM, Brown PH, Troncoso P, Logothetis CJ. A double-blind randomized controlled multisite trial evaluating tissue effects of preoperative finasteride in clinically organ-confined prostate cancer: Pathologic outcomes. AACR, 2013. e-Pub 2013.
58. Zurita AJ, Bischoff FZ, Gorlov I, Mayer JA, Pircher TJ, Mikolajczyk S, Logothetis C, Lin S, Cancer Center TUOTMA, Houston, TX, Inc B, Diego S, CA. Cadherin-11 (Cad11) for detection of epithelial-mesenchymal transition (EMT) in circulating prostate cancer (PCa) cells. ASCO, 2013. e-Pub 2013.
59. Aparicio AM, Gallichotte E, Cheng H, Yoo S, Maity S, Logothetis C, Tewari M. Circulating micro-RNAs can detect adaptive response to therapy and aggressive subset of prostate cancer. AACR, 2013. e-Pub 2013.
60. Kim J, Ward JF, Pettaway CA, Wang X, Kuban DA, Frank SJ, Lee A, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim MF, Hoffman KE, Pugh TJ, Choi S, Logothetis C, Troncoso P, Davis JW, Cancer Center TUOTMA, Houston, TX. Risk of missing advanced stage or high grade tumors during active surveillance (AS) even in favorable-risk prostate cancer (PC). ASCO, 2013. e-Pub 2013.
61. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev V, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, De Bono JS, Paliwal P, Durham S, Cheng S, Logothetis C, Medical Onology DOG, Cancer Center UOTMA, Houston, TX, Squibb B, Montreal, QC, Canada, de Montreal CHDL, Montreal, QC, Canada, Institute DC, Prostate Center TD, Medical Oncology DO, Urology, University D, Durham, NC, Washington UO, Care Alliance SC, Seattle, WA, del Mar-IMIM UH, Barcelona, Spain, Cancer Center UOWC, Madison, WI, Research Group ICO, Dublin, Ireland, de Barretos HDC, Paulo S, Brazil, Center NN, Moscow, Russia, Clinical Therapeutics DO, of Athens TU, Athens, Greece, Medical Oncology DO, European Hospital GP, Paris, France, Service GO, Cancer Center MS, York N, NY, Hospital EC, Colchester, Kingdom U, Urology DO, Friedrich-Alexander-Universitaet, Erlangen, Germany, Marsden Hospital IOCR, Sutton, Kingdom U, Squibb B, Wallingford, CT, Squibb B, Princeton, NJ. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. Genitourinary Cancers Symposium, 2013. e-Pub 2013.
62. Shore N, Basch E, Ryan CJ, Mulders P, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C. The impact of abiraterone acetate therapy on patient-reported pain and functional status in chemotherapy-naïve patients with progressive, metastatic castration-resistant prostate cancer – results from an updated analysis. AUA, 2013. e-Pub 2013.
63. Saad F, Shore ND, Poppel HV, Rathkopf D, Smith MR, de Bono JS, Logothetis C, Souza PD, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin T, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. Abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy – Interim analysis of the COU-AA-302 phase 3 trial. AUA, 2013. e-Pub 2013.
64. Rathkopf DE, Smith MR, De Bono JS, Logothetis C, Shore ND, De Souza PL, Fizazi K, Mulders P, Mainwaring PN, Hainsworth JD, Beer TM, North SA, Fradet Y, Griffin TW, Park YC, Kheoh TS, Small EJ, Scher HI, Molina A, Ryan CJ, Cancer Center MS, York N, NY, Cancer Center MGH, Boston, MA, Marsden Hospital IOCR, Sutton, Kingdom U, Cancer Center TUOTMA, Houston, TX, Research Center CU, Beach M, SC, of Medicine UOWSS, Institute I, Liverpool, Australia, Roussy IG, Villejuif, France, Medical Centre RU, Nijmegen, Netherlands, Haematology, of Australasia OC, Brisbane, Australia, Research Institute SC, Nashville, TN, Health O, University S, Institute KC, Portland, OR, Institute CC, Edmonton, AB, Canada, University L, Québec, QC, Canada, Research J, Development, Angeles L, CA, Research J, Development, Raritan, NJ, Cancer Center HDFC, California UO, Francisco S, CA, California UO, Francisco S, Francisco S, CA. Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. Genitourninary Cancers Symposium, 2013. e-Pub 2013.
65. Fizazi K, Pagliaro LC, Flechon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard J, Malhaire J, Linassier C, Habibian M, Journeau F, Logothetis C, Culine S, Laplanche A. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13. ASCO, 2013. e-Pub 2013.
66. Scher HI, Smith MR, Sweeney C, Corn PG, Logothetis C, Vogelzang NJ, Smith DC, Hussain M, George DJ, De Bono JS, Higano CS, Small EJ, Goldin J, Brown MS, Aftab DT, Noursalehi M, Weitzman A, Basch EM, Cancer Center MS, York N, NY, Cancer Center MGH, Boston, MA, Institute DC, Boston, MA, Cancer Center TUOTMA, Houston, TX, of Nevada CCC, Oncology Network TU, Vegas L, NV, Cancer Center UOMC, Arbor A, MI, Institute DC, Durham, NC, Cancer Research TIO, Foundation Trust TRMN, Sutton, Kingdom U, Research Center FHC, Seattle, WA, California UO, Francisco S, Francisco S, CA, California UO, Angeles L, Angeles L, CA, Computer Vision CF, Biomarkers I, California UO, Angeles L, CA, Exelixis, Inc, Francisco SS, CA. An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort. ASCO, 2013. e-Pub 2013.
67. Dayyani F, Nogueras-Gonzalez GM, Slack R, Millikan RE, Zurita AJ, Araujo JC, Gallick GE, Logothetis C, Corn PG, Cancer Center TUOTMA, Houston, TX, Cancer Center EH, Duluth, MN. Serum insulin to predict time to castration-resistant progression and overall survival in metastatic androgen-dependent prostate cancer (mADPCa). ASCO, 2013. e-Pub 2013.
68. Dayyani F, Varkaris A, Araujo JC, Song JH, Trudel GC, Logothetis C, Gallick GE, Cancer Center TUOTMA, Houston, TX, Squibb B, Montreal, QC, Canada. Serum insulin-like growth factor-1 levels in response to dasatinib-based regimens in bone-metastatic prostate cancer. Genitourninary Cancers Symposium, 2013. e-Pub 2013.
69. Palanisamy N, Yang J, Wan X, Araujo JC, Efstathiou E, Pisters L, Bhalla R, Tomlins S, Kunju LP, Chinnaiyan A, Logothetis CJ, Troncoso P, Navone NM. Xenografts of human prostate cancer - a genetic profile analysis. AACR, 2013. e-Pub 2013.
70. Ryan CJ, Smith MR, De Bono JS, Molina A, Logothetis C, De Souza PL, Fizazi K, Mainwaring PN, Piulats Rodriguez JM, Ng S, Carles J, Mulders P, Kheoh TS, Griffin TW, Small EJ, Scher HI, Rathkopf DE, COU-AA- Investigators OBOT, California UO, Francisco S, Francisco S, CA, Cancer Center MGH, Boston, MA, Hospital RM, Cancer Research IO, Sutton, Kingdom U, Research J, Development, Angeles L, CA, Cancer Center UOTMDA, Houston, TX, Hospital SG, Kogarah, Australia, Roussy IG, Villejuif, France, Haematology, of Australasia OC, Brisbane, Australia, de l'Hospitalet ICD, Barcelona, Spain, God Hospital SJO, Subiaco, Australia, Vall d'Hebron HU, Barcelona, Spain, Medical Centre RU, Nijmegen, Netherlands, Cancer Center MS, York N, NY. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). ASCO, 2012. e-Pub 2012.
71. Dayyani F, Araujo JC, Carboni JM, Gottardis MM, Trudel GC, Logothetis C, Gallick GE, Cancer Center UOTMDA, Houston, TX, Squibb B, Princeton, NJ, Squibb B, Wallingford, CT. Effect of inhibition of Src and insulin/insulin-like growth factor-1 receptor (IR/IGF-1R) on tumor activity and bone turnover in prostate cancer (PCa) models in vivo relative to inhibition of either kinase alone. ASCO, 2012. e-Pub 2012.
72. Efstathiou E, Titus M, Tsavachidou D, Wen S, Hoang A, Ashe R, Karlou M, Berman C, Troncoso P, Mohler J, LogothetisMDACC CJ, Houston, TX, Park R, Buffalo, NY, Medivation, Francisco S, CA. Modulation of intracrine androgen signaling in bone metastatic castrate resistant prostate cancer (bmCRPC) by MDV3100. AACR, 2012. e-Pub 2012.
73. Dayyani F, Parikh N, Song JH, Araujo JC, Carboni JM, Gottardis MM, Trudel GC, Logothetis C, Gallick GE, Cancer Center UOTMDA, Houston, TX, Squibb B, Princeton, NJ, Squibb B, Montreal, QC, Canada. Inhibition of Src and insulin/insulin-like growth factor-1 receptor (IR/IGF-1R) on tumors and bone turnover in prostate cancer (PCa) models in vivo compared with inhibition of either kinase alone. ASCO, 2012. e-Pub 2012.
74. Taplin M, Montgomery RB, Logothetis C, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Loda MF, True LD, Troncoso P, Genega EM, Balk SP, Nelson P, Xie W, Haqq CM, Tran N, Liu CS, Kheoh TS, Molina A, Kantoff P, Institute DC, Boston, MA, Washington UO, Seattle, WA, Cancer Center UOTMDA, Houston, TX, Medical Center BID, Boston, MA, Brigham, Hospital W, Boston, MA, Research Center FHC, Seattle, WA, Systems G, Francisco S, CA, Research J, Development, Angeles L, CA. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. ASCO, 2012. e-Pub 2012.
75. Efstathiou E, Assikis VJ, North SA, Showel J, Hutson TE, Riggs SB, Waxman J, Park YC, Kheoh TS, Haqq CM, Logothetis C, Molina A, Cancer Center UOTMDA, Houston, TX, Oncology Consultants PH, Atlanta, GA, Institute CC, Edmonton, AB, Canada, Institute RC, Medical Center RL, Chicago, IL, Research US, LLC, Health MS, Woodlands T, TX, and Baylor Sammons Cancer Center-Texas Oncology PA, Dallas, TX, Urology DO, University NS, Norfolk, VA, London IC, London, Kingdom U, Johnson, Research JP, Development, Raritan, NJ, Oncology Research OB, Development, Angeles L, CA. A hypothesis-generating exploratory analysis of efficacy and safety of abiraterone acetate (AA) in African American (Af Am) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). ASCO, 2012. e-Pub 2012.
76. Efstathiou E, Davis JW, Troncoso P, Titus MA, Hoang A, Wen S, Zurita AJ, Tran N, Molina A, Logothetis C, Athens UO, Athens, Greece, Cancer Center UOTMDA, Houston, TX, Cancer Center UOTMDA, Houston, TX, Cancer Institute RP, Buffalo, NY, Research J, Development, Angeles L, CA. Cytoreduction and androgen signaling modulation by abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus LHRHa in localized high-risk prostate cancer (PCa): Preliminary results of a randomized preoperative study. ASCO, 2012. e-Pub 2012.
77. Kleb BN, Estecio M, Zhang J, Tzelepi V, Chung W, Maity S, Logothetis C, Troncoso P, Navone N, Jelinek J, Liang S, Issa J, Cancer Center AAA, Houston, TX, Fels Institute TU, Philadelphia, PA. The DNA methylome of castration-resistant prostate cancer. AACR, 2012. e-Pub 2012.
78. P Gorlov BI, Byun J, Gorlova O, Logothetis C, Cancer Ctr HZMA, Houston, TX, Advanced Computing IO, Engineering D, Shenzhen, China. Selection vs modification in cancer. AACR, 2012. e-Pub 2012.
79. Chi KN, Scher HI, Molina A, Logothetis C, Jones RJ, Staffurth J, North SA, Vogelzang NJ, Saad F, Mainwaring PN, Harland SJ, Li J, Kheoh TS, Haqq CM, Fizazi K, Cancer Agency BC, Vancouver, BC, Canada, Cancer Center MS, York N, NY, Oncology Research OB, Development, Angeles L, CA, Cancer Center UOTMDA, Houston, TX, Cancer Sciences IO, Glasgow, Kingdom U, University C, Hospital V, Cardiff, Kingdom U, Institute CC, Edmonton, AB, Canada, of Nevada CCC, Vegas L, NV, Hospital Center UOM, Montreal, QC, Canada, Haematology, of Australasia OC, Milton, Australia, Cancer Institute UCL, London, Kingdom U, Johnson, Research JP, Development, Raritan, NJ, Roussy IG, Paris Sud UO, Villejuif, France. Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). ASCO, 2012. e-Pub 2012.
80. Smith MR, Sweeney C, Rathkopf DE, Scher HI, Logothetis C, George DJ, Higano CS, Yu EY, Harzstark AL, Small EJ, Sartor A, Gordon MS, Vogelzang NJ, Smith DC, Hussain M, De Bono JS, Haas NB, Scheffold C, Lee Y, Corn PG, Cancer Center MGH, Boston, MA, Institute DC, Boston, MA, for Prostate SKC, Cancers U, Cancer Center MS, York N, NY, Cancer Center UOTMDA, Houston, TX, Medical Center DU, Durham, NC, Research Center FHC, Seattle, WA, California UO, Francisco S, Francisco S, CA, Center TC, Orleans N, LA, Hematology PO, Scottsdale, AZ, US Oncology Research/Comprehensive Cancer Centers NV, Vegas L, NV, Michigan UO, Arbor A, MI, Cancer Center UOMC, Arbor A, MI, Hospital RM, Cancer Research IO, Sutton, Kingdom U, of Pennsylvania ACCATU, Philadelphia, PA, Exelixis, Francisco SS, CA. Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE). ASCO, 2012. e-Pub 2012.
81. Basch EM, De Bono JS, Scher HI, Molina A, Sternberg CN, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Farr AM, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Efstathiou E, Logothetis C, Cancer Center MS, York N, NY, Cancer Research TIF, Hospital RM, Sutton, Kingdom U, Oncology Research OB, Development, Angeles L, CA, Camillo S, Hospitals F, Rome, Italy, Roussy IG, Villejuif, France, Institute CC, Edmonton, AB, Canada, Cancer Agency BC, Vancouver, BC, Canada, Cancer Sciences IO, Glasgow, Kingdom U, Medical Group NCI, Vegas L, NV, Haematology, of Australasia OC, Milton, Australia, Reuters T, Washington, DC, Services JG, Raritan, NJ, Cancer Center UOTMDA, Houston, TX. Pain control and delay in time to skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA): Long-term follow-up. ASCO, 2012. e-Pub 2012.
82. Goodman OB, Chi KN, Molina A, Logothetis C, Jones RJ, Staffurth J, North SA, Vogelzang NJ, Saad F, Mainwaring PN, Harland SJ, Li J, Kheoh TS, Haqq CM, Scher HI, Fizazi K, Institute NC, Vegas L, NV, Cancer Agency BC, Vancouver, BC, Canada, Research J, Development, Angeles L, CA, Cancer Center UOTMDA, Houston, TX, Cancer Sciences IO, Glasgow, Kingdom U, University C, Hospital V, Cardiff, Kingdom U, Institute CC, Edmonton, AB, Canada, of Nevada CCC, Research US, Vegas L, NV, Montreal UO, Montreal, QC, Canada, Haematology, of Australasia OC, Brisbane, Australia, Institute UCL, London, Kingdom U, Research J, Development, Raritan, NJ, Systems G, Francisco S, CA, Cancer Center MS, York N, NY, Roussy IG, Villejuif, France. Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). ASCO, 2012. e-Pub 2012.
83. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ. Characterization of castrate resistant prostate cancer treated with abiraterone acetate and prednisone. AACR(#LB-421), 2011. e-Pub 2011.
84. Tzelepi V, Maity S, Zhang J, Liang S, Lu JF, Hoang A, Kleb B, Efstathiou E, Navone N, Troncoso P, Logothetis C, Aparicio A. Molecular profiling of prostate cancer xenografts and human specimens reveals overexpression of UBE2C/UBCH10 and activation of aurora kinases in poorly differentiated neuroendocrine carcinoma of the prostate. AACR(#36), 2011. e-Pub 2011.
85. Zhao H, Logothetis CJ, Gorlov IP. Exploratory analysis of the usefulness of the top-scoring pairs (TSP) of genes for prediction of prostate cancer progression. AACR(#1990), 2010. e-Pub 2010.
86. Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn P. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. AACR(#5509), 2009. e-Pub 2009.
87. Efstathiou E, Wen S, Molina A, Chieffo N, Smith L, Hoang A, Troncoso P, Logothetis CJ. Candidate predictors of response to abiraterone acetate (AA) in castrate-resistant prostate cancer (CRPC). J Clin Oncol 27, 2009. e-Pub 2009.
88. Sharma P, Tsavachidou D, Kamat A, Ng Tang D, Chen H, Fu T, Troncoso P, Wolchok J, Logothetis CJ, Allison JP. Immunologic impact of anti-CTLA-4 therapy. J Clin Oncol 27, 2009. e-Pub 2009.
89. Li J, Mills GB, Huang M, Lin SH, Logothetis CJ, Kim J. Differential and cell type-dependent transcriptional regulation of SRD5A1, SRD5A2, and SRD5A3 in the androgen receptor pathway in prostate cancer. AACR(#935), 2009. e-Pub 2009.
90. Ryan CJ, Efstathiou E, Smith M, Taplin M, Bubley G, Logothetis CJ, Kheoh T, Haqq CM, Molina A, Small EJ. Abiraterone acetate plus prednisone in chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) patients not exposed to ketoconazole: Results of a multicenter phase II study. J Clin Oncol 27, 2009. e-Pub 2009.
91. Zurita AJ, Liu G, Hutson T, Kozloff M, Shore N, Wilding G, Logothetis CJ, Chen I, Chow Maneval E, George D. Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC). J Clin Oncol 27, 2009. e-Pub 2009.
92. Sharma P, Kamat A, Tang DN, Chen H, Fu T, Sun J, Troncoso P, Yuan J, Wolchok J, Quezada S, Logothetis CJ, Allison JP. Assessing immunologic impact of anti-CTLA-4 therapy on a pre-surgical clinical trial. AACR(#5665), 2009. e-Pub 2009.
93. Johnson ED, Tannir NM, Logothetis CJ, Jonasch E. Survival benefit in bevacizumab based therapy in sickle cell trait patients diagnosed with renal medullary carcinoma. J Clin Oncol 27, 2009. e-Pub 2009.
94. Gorlov IP, Byun JY, Gorlova O, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. AACR(#5205), 2009. e-Pub 2009.
95. Araujo J, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086). J Clin Oncol 27, 2009. e-Pub 2009.
96. Yamamura Y, Pettaway CA, Logothetis CJ, Strom SS. Different risk factors for prostate cancer among obese and non-obese Mexican American men. AACR(#4829), 2009. e-Pub 2009.
97. Yamamura Y, Pettaway C, Pollak M, Barrera S, Logothetis CJ, Strom S. Saturated fat intake predicts biochemical failure among prostatectomy patients. AACR(#3399), 2008. e-Pub 2008.
98. Tu S, Jones D, Mathew P, Logothetis CJ. Phase I study of concurrent weekly docetaxel (Tax) and repeated 153Sm-lexidronam (Sam) in androgen-independent prostate cancer (AIPC). J Clin Oncol 26, 2008. e-Pub 2008.
99. Pataer A, Swisher S, Roth J, Logothetis CJ, Corn P. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. AACR(#5509), 2008. e-Pub 2008.
100. Li J, Mills G, Huang M, Lin SH, Logothetis CJ, Kim J. Differential and cell type-dependent transcriptional regulation of SRD5A1, SRD5A2, and SRD5A3 in the androgen receptor pathway in prostate cancer. AACR(#935), 2008. e-Pub 2008.
101. Zurita AJ, Ward JF, Araujo JC, Pettaway CA, Pisters LL, Dieringer P, Troncoso P, Logothetis CJ. Presurgical sunitinib malate and androgen ablation in patients with localized prostate cancer at high risk for recurrence. J Clin Oncol 26, 2008. e-Pub 2008.
102. George DJ, Liu G, Wilding G, Hutson TE, Chen I, Maneval E, Logothetis CJ, Zurita AJ. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary results. J Clin Oncol 26, 2008. e-Pub 2008.
103. Li ZG, Yingling JM, Logothetis CJ, Navone NM. TGFß1 receptor kinase inhibitor inhibits prostate cancer growth in bone. AACR(#687), 2008. e-Pub 2008.
104. Sharma P, Kamat A, Tang DN, Chen H, Fu T, Sun J, Troncoso P, Yuan J, Wolchok J, Quezada S, Logothetis CJ, Allison J. Assessing immunologic impact of anti-CTLA-4 therapy on a pre-surgical clinical trial. AACR(#5665), 2008. e-Pub 2008.
105. Mathew P, Pagliaro LC, Tannir NM, Tu S, Marcott V, Patterson L, Reed K, Bekele N, Logothetis CJ. Single-agent platelet-derived growth factor (PDGF) receptor inhibitor therapy for castration-resistant prostate cancer with bone metastases. J Clin Oncol 26, 2008. e-Pub 2008.
106. Gorlov I, Byun JY, Gorlova O, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. AACR(#5205), 2008. e-Pub 2008.
107. Spurgers KB, Rolle G, Gold DL, Bohnenstiehl N, Coombes KR, Meyn RE, Logothetis CJ, McDonnell TJ. Cell cycle regulatory genes are principal targets of p53-dependent, RB-mediated transcriptional repression following DNA damage. AARC(#591), 2008. e-Pub 2008.
108. Strom SS, Yamamura Y, Pettaway CA, Logothetis CJ, Troncoso P, Do KA. Clinical, epidemiologic and molecular factors as predictors of time to biochemical failure among prostatectomy patients. AACR(#113), 2008. e-Pub 2008.
109. Efstathiou E, Tsavachidou D, Wen S, Troncoso P, Mills GB, Logothetis CJ. Integrated quantative and spatial proteomic analysis of PI3kinase signaling in high grade prostate cancer (PCa) treated with Temsirolimus with or without androgen ablation. J Clin Oncol 26, 2008. e-Pub 2008.
110. Yamamura Y, Pettaway C, Logothetis CJ, Strom S. Different risk factors for prostate cancer among obese and non-obese Mexican American men. AACR(#2429), 2008. e-Pub 2008.
111. Aparicio AM, Lin AM, Araujo JC, Logothetis CJ, Kim J, Pagliaro LC, Tu S, Guo C, Jones D, Thall P, Mathew P. Use of clinical features to select a chemotherapy-responsive variant of aggressive prostate cancer (PC). J Clin Oncol 26, 2008. e-Pub 2008.
112. Kim J, Vakar-Lopez F, Thall PF, Wang X, Stephens CL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Pereira P, Soto C, Menter DG, Lieberman R, McDonnell TJ, Lippman SM, Sabichi AL, Logothetis CJ, Troncoso P. The effects of selenium and vitamin E on apoptosis and proliferation in prostate tissue from a preprostatectomy study in patients with clinically organ-confined prostate cancer. AACR(#379), 2008. e-Pub 2008.
113. Logothetis CJ, Wen S, Molina A, Chieffo N, Smith LA, Troncoso P, Efstathiou E. Identification of an androgen withdrawal responsive phenotype in castrate resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA). J Clin Oncol 26, 2008. e-Pub 2008.
114. Efstathiou E, Troncoso P, Wen S, Do K, Pettaway CA, Logothetis CJ. Coordinated modulation of sonic hedgehog (Shh) signaling and androgen receptor (AR) in the prostate tumor microenvironment by chemo-hormonal therapy. Proc ASCO 25, 2007. e-Pub 2007.
115. Mathew P, Pettaway C, Pisters L, Williams D, Troncoso P, Logothetis C. Preoperative platelet-derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation in high-risk localized prostate cancer. Proc ASCO 25, 2007. e-Pub 2007.
116. Kim J, Tsavachidou D, Do K, Wen S, Babaian R, Pisters L, Pettaway C, Troncoso P, Logothetis C, McDonnell T. Differential gene expression in preoperative study of selenium and vitamin E chemoprevention in prostate cancer. Proc ASCO 25, 2007. e-Pub 2007.
117. Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TM, Maneval EC, Chen I, Logothetis CJ. Distinct patterns of PSA modulation by single-agent sunitinib before combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPCa). Proc ASCO 25, 2007. e-Pub 2007.
118. Fizazi K, Hudes GR, Berry WR, Kelly WK, Eymard JC, Logothetis C, Maitre A, Pignon JP, Michiels S. A meta-analysis of individual patient data from randomized trials assessing chemotherapy with and without estramustine in patients with castration-refractory prostate cancer. Proc ASCO 24, 2006. e-Pub 2006. PMID: 17942366.
119. Kim J, Wang X, Babaian R, Pisters L, Pettaway C, Wood C, Sabichi A, McDonnell T, Logothetis C, Troncoso P. A preoperative model evaluating the tissue effects of chemopreventive agents in low-volume prostate cancer. Proc ASCO 24, 2006. e-Pub 2006.
120. Mathew P, Thall PF, Johnson MM, Oh WK, Meluch AA, Morris MJ, Troncoso P, Bucana CD, Fidler IJ, Logothetis CJ. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). Proc ASCO 24, 2006. e-Pub 2006.
121. AOSiefker-Radtke, VPoulter, PMathew, S-MTu, CJLogothetis, CNPapandreou. Preliminary evidence of efficacy and tolerance for weekly intravenous bortezomib plus mitoxantrone in patients with advanced androgen-independent prostate cancer (AIPCa). . Proc ASCO 23, 2005. e-Pub 2005.
122. EJonasch, S-MTu, NMTannir, LCPagliaro, PMathew, AOSiefker-Radtke, SWen, RGeneral, S-HLin, CJLogothetis. Bone-Targeted therapy consisting of zoledronate, thalidomide, and gamma interferon in renal cell carcinoma: a phase II study. Proc ASCO 23, 2005. e-Pub 2005.
123. S-MTu, JKim, LCPagliaro, FVakar-Lopez, FCWong, SWen, RGeneral, DAPodoloff, S-HLin, CJLogothetis. Long-term effects of strontium-89 combined with chemotherapy in patients with androgen-independent prostate cancer and bone metastases. Proc ASCO 23, 2005. e-Pub 2005.
124. SMao, DDaliani, XWang, K-ADo, PFThall, CAPerez, MABrown, CJLogothetis, JKim. Phase II randomized, placebo-controlled, double-blind study of IM862 plus a short course of androgen ablation for patients with androgen-dependent prostate cancer who failed local therapies: A platform for new drug screening. Proc ASCO 23, 2005. e-Pub 2005.
125. PMathew, JYang, S-JKim, IFidler, CBucana, PTroncoso, XWang, PThall, CLogothetis, NNavone. Proc ASCO 23, 2004. e-Pub 2004.
126. AJZurita, AHajitou, MCardo-Vila, PTroncoso, CJLogothetis, RPasqualini, WArap. Proc ASCO 23, 2004. e-Pub 2004.
127. REMillikan, PThall, LPagliaro, DWilliams, MBrown, CLogothetis. Randomized, adaptive, phase II selection trial of four chemotherapy regimens in androgen independent prostate cancer (AIPC). Proc ASCO 23, 2004. e-Pub 2004.
128. PMathew, PThall, DJones, CPerez, CBucana, S-JKim, IFidler, CLogothetis. Targeting the platelet-derived growth factor receptor (PDGFr) in androgen-independent prostate cancer (AIPCa) bone metastases: Results of a phase I trial. Proc ASCO 22, 2003. e-Pub 2003.
129. VJAssikis, DDaliani, LPagliaro, CWood, CPerez, CLogothetis, CPapandreou, ESHawkins, PKSrivastava. Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). Proc ASCO 22, 2003. e-Pub 2003.
130. KFizazi, AKramar, SCuline, IChen, J-PDroz, CJLogothetis. The early decline of tumor markers predicts outcome in poor-prognosis non-seminomatous germ-cell tumors (NSGCT): results of a multi-institution study. Proc ASCO 21, 2002. e-Pub 2002.
131. VJAssikis, CLogothetis, PThall, JPutnam, S-MTu, DSwanson, XWang, CPapandreou, DDaliani. A prospective study of salvage surgery and additional systemic therapy following initial response in metastatic renal cell carcinoma (RCC). Proc ASCO 21, 2002. e-Pub 2002.
132. Siefker-Radtke AO, Walsh GL, Swanson DA, Logothetis C, Millikan RE. Is There a Role for Surgery in the Management of Metastatic Urothelial Cancer: The M. D. Anderson Experience. Proc ASCO 20, 2001. e-Pub 2001.
133. Papandreou C, Daliani D, Millikan RE, Tu S, Pagliaro L, Adams J, Elliott P, Nix D, PDieringer, Thall P, Logothetis CJ. Phase I Study of Intravenous (I.V.) Proteasome Inhibitor PS-341 in Patients (Pts.) with Advanced Malignancies. Proc ASCO 20, 2001. e-Pub 2001.
134. Li Z, Amato R, Papandreou C, Pagliaro L, Kim J, Millikan R, Loggins-Coffman J, Perez C, Logothetis C, Daliani D. Phase II Study of Thalidomide for Patients with Metastatic Renal Cell Carcinoma (MRCC) Progressing After Interleukin-2 (IL-2)-Based Therapy (Rx). Proc ASCO 20, 2001. e-Pub 2001.
135. Logothetis CJ, Yang H, Daliani D, Millikan RE, Tu S, Pagliaro L, Adams J, Elliott P, Nix D, Dieringer P, Papandreou CN. Dose Dependent Inhibition of 20S Proteasome Results in Serum IL-6 and PSA Decline in Patients (PTS) with Androgen-Independent Prostate Cancer (AI PCa) Treated with the Proteasome Inhibitor PS-341. Proc ASCO 20, 2001. e-Pub 2001.
136. Assikis VJ, Tu S, Papandreou C, Mengistu B, Holtkamp T, Pagliaro L, Millikan R, Logothetis C, Daliani D. Phase II Study of Cyclophosphamide (CTX), Vincristine (VCR), Dexamethasone (DEX) (CVD) for Patients with Metastatic Androgen Independent Adenocarcinoma of the Prostate (AIPCa). Proc ASCO 20, 2001. e-Pub 2001.
137. Wang L, Elgamal A, Shankar G, Lodge P, Salgaller M, Boynton AL, Fiorentino A, Dalini D, Tu S, Pagliaro L, Logothetis CJ, Papandreou C. rPSMA-Loaded Autologous Dendritic Cell Vaccine (CaPVax) Safely Activates Cellular and Humoral Immune Responses Against Androgen-Independent Prostate Cancer. Proc ASCO 20, 2001. e-Pub 2001.
138. Tu S, Vassilopoulou-Sellin R, Jr H, Wong S, Logothetis C. Elevated Testosterone Level in Prostate Cancer Patients Following Castration: Role of Nutritional Factors. Proc ASCO 20, 2001. e-Pub 2001.
139. Pisters LL, McDonnell TJ, Troncoso P, Brisbay S, Hossan E, Pettaway C, Wood C, Evans R, Steiner M, Merritt J, Logothetis C. Intraprostatic Ad-p53 Gene Therapy Induces Apoptosis in Locally Advanced Adenocarcinoma of the Prostate. Proc ASCO 20, 2001. e-Pub 2001.

Book Chapters

1. Sanford RA, Abudayyeh A, Logothetis CJ, Tannir, NM. Urologic complications. In: Holland-Frei Cancer Medicine 9th Edition. Ninth. Wiley-Blackwell, 1755-1762, 2017.
2. Logothetis CJ, Kim J, Davis JW, Chapin BF, Kuban D, Efstathiou E, Aparicio A. Neoplasms of the prostate. In: Holland-Frei Cancer Medicine 9th Edition. Ninth. Wiley-Blackwell, 1205-1235, 2017.
3. Bilen MA, Logothetis CJ, Corn PG. Chapter 37: Prostate Cancer. In: The MD Anderson Manual of Medical Oncology, Third Edition. Third. McGraw-Hill Education, 773-791, 2016.
4. Corn P, Logothetis CJ. Chapter 34: Prostate Cancer. In: The MD Anderson Manual of Medical Oncology, 2e. The McGraw-Hill Companies, 2011.
5. Efstathiou E, Logothetis CJ. Clinical Challenges for Treatment and a Cure. In: The Biology and Treatment of Cancer. John Wiley & Sons, Inc, 155-67, 2008.
6. Logothetis CJ. Strategy for the application of therapy in prostate cancer. In: Adv Exp Med Biol, 193-9, 2008.
7. Logothetis CJ, Assikis V, Sarriera JE. Urologic Complications. In: Holland-Frei Cancer Medicine 6th Editition. BC Decker Inc, 2003.
8. Logothetis CJ, Moon C. Chapter 225-Endocrine Aspects of Prostate Cancer. In: Principles and Practice of Endocrinology and Metabolism, 2000.
9. Logothetis CJ, Vogelzang NJ. Chapter 46B-Current Treatment and Investigative Approaches to the Management of Hormone-Refractory Prostate Cancer. In: Comprehensive Textbook of Genitourinary Oncology, 862-869, 1999.
10. Hossan Eand Logothetis CJ. Chapter 10 - Management of hormone refractory disease. In: International Handbook of Prostate Cancer, 137-148, 1999.
11. Scher HI, Logothetis CJ. Management of androgen-independent prostatic cancer. In: Principles and Practices of Genitourinary Oncology. Lippincott-Raven, 599-612, 1997.
12. Logothetis CJ. Urological complications of malignancies and cancer therapy. In: Cancer Medicine 4th Edition. Williams and Wilkins, 3191-3196, 1997.
13. Logothetis, CJ, Hoosein NM, Ro JY. Neuroendocrine progression of prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology. Williams and Wilkins, 914-919, 1996.
14. Amato RJ, Logothetis CJ. Chemotherapy for stage I and II testicular cancer. In: Comprehensive Textbook of Genitourinary Oncology. Williams and Wilkins, 1022-1027, 1996.
15. Denis L, Logothetis CJ. Urothelial cancer: The role of haematopoietic growth factors. In: Consultant Series - Urothelial Cancer. Gardiner-Caldwell Biotech, 1996.
16. Amato, R, Finn L, Striegel A, Sella A, Ellerhorst J, Zukiwski A, Logothetis CJ. Salvage therapy in metastatic non-seminomatous germ cell tumour at the University of Texas M. D. Anderson Cancer Center. In: Germ Cell Tumours III, 271-272, 1994.
17. Sella, A, Finn L, Amato R, Ellerhorst J, Zukiwski A, Kilbourn R, Logothetis CJ. Interferon- (IFN-) Combined with 5-Fluorouracil (5-FU) is an Active Regimen in Metastatic Renal Cell Cancer (RCC). In: Cancer Treatment: An Update. Springer-Verlag, 535-539, 1994.
18. Preti HA, Logothetis CJ. Testicular Cancer. In: Medical Oncology: A Comprehensive Review. PRR, Inc, 295-311, 1993.
19. Logothetis CJ. The management of androgen-independent prostatic carcinoma. In: Prostate Diseases. W. B. Saunders Co, 364-3676, 1993.
20. Dexeus F, Logothetis CJ. Penile carcinoma. In: Handbook of Chemotherapy in Clinical Oncology (2nd Edition). Scientific Communication International Ltd, 565-567, 1993.
21. Sella, A, Amato RJ, Fitz K, Kilbourn RG, Logothetis CJ. Interferon-alpha and 5-fluorouracil combination chemotherapy for metastatic renal cell cancer. In: Interferons and Cytokines, 17-21, 1992.
22. Kilbourn, RG, Owen-Schaub L, Griffith OW, Logothetis CJ. IL-2 mediated hypotension in the awake dog is reversed by inhibitors of nitric oxide formation. In: Second International Meeting - Biology of Nitric Oxide. Portland Press Ltd, 1991.
23. Logothetis, CJ, Dexeus FH, CD-K C, Sella A, Ogden S. The impact of chemotherapy on the survival of patients with metastatic urothelial tumors. In: Uro-Oncology: Current Status and Future Trends. Alan R. Liss, Inc, 107-114, 1990.
24. Logothetis, CJ, CD-K C, Dexeus FH, Sella A, Ogden S. Intensive chemotherapy for metastatic nonseminomatous germ cell tumors. In: Uro-Oncology: Current Status and Future Trends. Alan R. Liss, Inc, 301-307, 1990.
25. Wallace, S, Charnsangavej C, Carrasco CH, Logothetis CJ. Intra-arterial chemotherapy of genitourinary tumors. In: Clinical Urography. W. B. Saunders Company, 3018-3026, 1990.
26. Logothetis, CJ, Johnson DE, von Eschenbach A. Germ cell tumors: Commentary. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 380-384, 1989.
27. Chong C, Logothetis CJ. Chemotherapy for extragonadal germ cell tumors: The M. D. Anderson experience. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 363-369, 1989.
28. Logothetis CJ. Postoperative adjuvant CISCA chemotherapy for high risk invasive bladder cancer. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 73-76, 1989.
29. Johnson, DE, von Eschenbach A, Logothetis CJ. Renal cell carcinoma: Commentary. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers,, 140-142, 1989.
30. Sella, A, Logothetis CJ, Dexeus FH, Amato RJ, Ogden S. Long-term cure rate in 154 testicular nonseminomatous germ cell tumor (NSGCTT) patients treated with aggressive chemotherapy. In: Proceedings of the 16th International Congress of Chemotherapy. June, 1989.
31. Chong CDK, Logothetis CJ. Cisplatin-based chemotherapy for metastatic pure seminoma. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers,, 280-285, 1989.
32. Dexeus, FH, Logothetis CJ, Sipahi H. Chemotherapy for advanced squamous carcinoma of the male external genital tract and urethra. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 255-259, 1989.
33. Johnson, DE, Logothetis CJ, von Eschenbach A. Urinary tract tumors: Commentary. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 101-104, 1989.
34. Logothetis CJ. CISCA chemotherapy for disseminated bladder carcinoma. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 43-47, 1989.
35. Logothetis, CJ, Dexeus F, Chong C, Sella A, Finn L. Cytotoxic chemotherapy for hormone-refractory metastatic prostate cancer. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 234-238, 1989.
36. Eschenbach V, AC, Johnson DE, Logothetis CJ. Prostate cancer: Commentary. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers,, 251-254, 1989.
37. Logothetis, CJ, Chong CDK, Ogden S. Long term follow-up of patients treated with cyclic CISCAII/VBIV at the University of Texas M. D. Anderson Cancer Center. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 349-355, 1989.
38. Chong C, Logothetis CJ. Treatment of advanced transitional cell carcinoma of the renal pelvis and ureter. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 94-100, 1989.
39. Logothetis, CJ, Swanson D, Ogden S. Primary chemotherapy for retroperitoneal nodal disease (clinical stage II). In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 326-330, 1989.
40. Logothetis CJ, Ro JY. Germ cell tumors: Clinically relevant advances. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 272-279, 1989.
41. Logothetis, CJ, Chong C, Dexeus FH, Sella A, Ogden S. Intensive chemotherapy for metastatic nonseminomatous germ cell tumors. In: Uro-Oncology: Current Status and Future Trends. Alan R. Liss, Inc, 301-307, 1988.
42. Swanson DA, Logothetis CJ. Primary chemotherapy for clinical stage II nonseminomatous testicular carcinoma. In: Advances in Urology. Year Book Medical Publishers, Inc, 129-144, 1988.
43. Swanson DA, Logothetis CJ. Metastatic transitional cell carcinoma. In: Current Therapy in Genitourinary Surgery. B. C. Decker Inc, 69-73, 1987.
44. Logothetis CJ. Testicular cancer and other tumors of the male genitourinary tract. In: Cancer Chemotherapy by Infusion. Precept Press Inc, 353-367, 1987.
45. Logothetis CJ. Vinblastine and bleomycin combination in the management of germ cell tumors (Part I); Prostatic carcinoma (Part II); Urothelial tumors (Part III). In: Cancer Chemotherapy by Infusion. Precept Press Inc, 353-367, 1987.
46. Logothetis, CJ, Johnson DE, Chong C, Dexeus FH, Ogden S, von Eschenbach AC, Ayala AG. Adjuvant CISCA for patients with high risk bladder cancer. In: Adjuvant Therapy of Cancer V. Grune and Stratton, Inc, 565-570, 1987.
47. Logothetis CJ. Testicular cancer. In: Cancer Update 87: Committee of Medical Oncology Fellows Board Review, M. D. Anderson Hospital and Tumor Institute, 1987.
48. Johnson, DE, Logothetis CJ, Zagars GK, Smith DB. Special problems posed by cancer treatments. In: Ostomy Care and the Cancer Patient. Surgical and Clinical Considerations. Grune and Stratton, Inc, 121-131, 1986.
49. Logothetis CJ. Extragonadal germ cell tumors. In: Principles and Management of Testicular Cancer. Thieme Inc, 355-350, 1986.
50. Logothetis CJ. Preoperative chemotherapy in the treatment of germinal tumors. In: Primary Chemotherapy in Cancer Medicine. Alan R. Liss, Inc, 341-350, 1985.
51. Logothetis CJ. Perioperative chemotherapy for the management of primary local regional urothelial tumors. In: Primary Chemotherapy in Cancer Medicine. Alan R. Liss, Inc, 359-366, 1985.
52. Logothetis, CJ, von Eschenbach AC, Samuels ML, Trindade A, Johnson DE. Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: A preliminary report. In: Year Book of Cancer, 134-136, 1983.

Letters to the Editor

1. Logothetis CJ, Hahn AW. Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7. Eur Urol 85: e175, 2024.
2. Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ. Reply by Authors. J Urol 206: 1156, 2021.
3. Pagliaro LC, Tannir NM, Tu SM, Logothetis CJ. Management of Clinical Stage I Testicular Cancer: How Should We Define Success?. J Clin Oncol 33: 2321-2, 2015.
4. Tu SM, Lin SH, Logothetis C. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 95: 1174-5; author reply 1175, 2003.
5. von Eschenbach AC, Logothetis CJ. Prostate Cancer. Cancer Bulletin 45: 379-380, 1993.
6. Logothetis CJ, Amato RJ. Dose intensity in germ cell tumors: lessons learned?. J Natl Cancer Inst 84: 1686-7, 1992.
7. Logothetis CJ. Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Progress in Clinical and Biological Research. Journal of the National Cancer Institute 83: 786, 1991.
8. Logothetis CJ. Organ Preservation in Bladder Carcinoma: A Matter of Selection. Journal of Clinical Oncology 9: 1525-1526, 1991.
9. Sella A, Logothetis CJ, Dexeus FH, Amato R. Pulmonary air cyst associated with combination chemotherapy containing bleomycin. AJR Am J Roentgenol 153: 191, 1989.
10. Logothetis CJ. Adjuvant chemotherapy for testicular cancer. N Engl J Med 319: 53, 1988.
11. Logothetis CJ. Carcinoma-in-situ of the testis. Lancet 2: 977, 1987.
12. Logothetis CJ. Have aggressive chemotherapy regimens improved results in advanced germ cell tumors. Eur J Cancer Clin Oncol 23: 1415-6, 1987.
13. Logothetis CJ. Lhermittes sign following cisplatin therapy for a patient with CISCAII/VBIV (editorial). American Journal of Medicine 82: 575-576, 1987.
14. Logothetis CJ, Samuels ML. Prognostic factors in disseminated germ cell tumors. J Clin Oncol 4: 1278-80, 1986.
15. Logothetis CJ. Endodermal sinus tumors. Chest 88: 6-7, 1985.
16. Logothetis CJ. Bladder cancer histology reported to influence response to treatment (editorial). Urology Times 1: 380, 1984.